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The primary purpose of the National Antimicrobial Resistance Monitoring System (NARMS) at the Centers for 
Disease Control and Prevention (CDC) is to monitor antimicrobial resistance among enteric bacteria isolated from 
humans. Other components of the interagency NARMS program include surveillance for resistance in enteric 
bacteria isolated from retail meats, conducted by the U.S. Food and Drug Administration’s Center for Veterinary 
Medicine (FDA-CVM) 
(http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMoni
toringSystem/default.htm), and for resistance in enteric bacteria isolated from food-producing animals, conducted 
by the U.S. Department of Agriculture’s Agricultural Research Service (USDA-ARS) 
(http://www.ars.usda.gov/Business/docs.htm?docid=6750&page=1) and Food Safety and Inspection Service 
(USDA-FSIS) (http://www.fsis.usda.gov/OPPDE/rdad/FSISNotices/13-13.pdf?redirecthttp=true).  
 
Many NARMS activities are conducted within the framework of two CDC programs: the Foodborne Diseases 
Active Surveillance Network (FoodNet), which is part of CDC’s Emerging Infections Program (EIP), and the 
Epidemiology and Laboratory Capacity (ELC) Program. In addition to population-wide surveillance of resistance in 
enteric pathogens, the NARMS program at CDC also conducts research into the mechanisms of resistance and 
performs susceptibility testing of isolates of pathogens that have caused outbreaks. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with ongoing monitoring of antimicrobial resistance among clinical isolates of non-Typhi Salmonella (refers 
to all serotypes other than Typhi, which causes typhoid fever) and Escherichia coli O157 in 14 sites. In 1997, 
testing of clinical isolates of Campylobacter was initiated in the five sites then participating in FoodNet. Testing of 
clinical Salmonella ser. Typhi and Shigella isolates was added in 1999. Starting in 2003, all 50 states forwarded 
all Salmonella ser. Typhi isolates and a representative sample of non-Typhi Salmonella, Shigella, and E. coli 
O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 states now participating in FoodNet have 
been conducting Campylobacter surveillance. Since 2008, all 50 states have also been forwarding every 
Salmonella ser. Paratyphi A and C to NARMS for antimicrobial susceptibility testing. Beginning in 2009, NARMS 
also performed susceptibility testing on isolates of Vibrio species other than V. cholerae. Public health 
laboratories are asked to forward every isolate of Vibrio species that they receive to CDC. All toxigenic V. 
cholerae isolates are tested for antimicrobial susceptibility by the National Enteric Laboratory Diagnostic Outbreak 
Team; results are available in the Cholera and Other Vibrio Illness Surveillance system (COVIS) reports 
beginning with the 2013 Annual Summary. NARMS conducts antimicrobial susceptibility testing for isolates of 
species other than V. cholerae; results are included in this report.   
 
This annual report includes CDC’s surveillance data for 2013 for nontyphoidal Salmonella, typhoidal Salmonella 
(serotypes Typhi, Paratyphi A, Paratyphi B [tartrate negative], and Paratyphi C), Shigella, Campylobacter, E. coli 
O157, and Vibrio species other than V. cholerae. Surveillance data include the number of isolates of each 
pathogen tested by NARMS and the number and percentage of isolates that were resistant to each of the 
antimicrobial agents tested. Data for earlier years are presented in tables and graphs when appropriate. 
Antimicrobial classes defined by the Clinical and Laboratory Standards Institute (CLSI) are used in data 
presentation and analysis.   
 
This report uses the World Health Organization’s categorization of antimicrobials of critical importance to human 
medicine (Appendix A) in the tables that present minimum inhibitory concentrations (MIC) and resistant 
percentages.  
 
Additional NARMS data and more information about NARMS activities are available at http://www.cdc.gov/narms/. 
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New Baselines for Assessing Changes in Prevalence of Antimicrobial Resistance 
 
To assess changes in the prevalence of antimicrobial resistance among Salmonella, Shigella, and Campylobacter 
isolates, NARMS models annual data using logistic regression. In previous reports, we compared the prevalence 
of resistance for the current year to the average prevalence during a historical baseline reference period of 2003–
2007. In this report, we compared the prevalence of resistance among isolates tested in 2013 with the average 
prevalence from two reference periods: 2004–2008 and the previous five years, 2008–2012. The 2004–2008 
reference period begins with the second year that all 50 states participated in Salmonella and Shigella 
surveillance and all 10 FoodNet sites participated in NARMS Campylobacter surveillance. The additional 2008–
2012 reference period allows comparison with more recent years. The results of these analyses can be found on 
pages 17–18. 
 
 
Changes in Antimicrobial Susceptibility Testing for Vibrio Species other than V. cholerae 
 
Since 2009, NARMS has tested Vibrio species other than V. cholerae to determine the minimum inhibitory 
concentrations for ampicillin, cephalothin, chloramphenicol, ciprofloxacin, kanamycin, nalidixic acid, streptomycin, 
tetracycline, and trimethoprim-sulfamethoxazole. In 2013, we added four antimicrobial agents to the panel: 
cefotaxime, ceftazidime, gentamicin, and imipenem. To accommodate these additions, cephalothin, kanamycin, 
and streptomycin were removed. Further details regarding testing can be found on page 29, and susceptibility 
results can be found in the Vibrio species other than V. cholerae section of this report. 
 
  
What is New in the NARMS Report for 2013 
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Surveillance Population  
 
In 2013, all 50 states and the District of Columbia participated in NARMS, representing the entire US population 
of approximately 316 million persons (Table 1). Surveillance was conducted in all states for Salmonella (typhoidal 
and nontyphoidal), Shigella, Escherichia coli O157, and Vibrio species other than V. cholerae. For 
Campylobacter, surveillance was conducted in the 10 states that comprise the Foodborne Diseases Active 
Surveillance Network (FoodNet), representing approximately 48 million persons (15% of the US population).  
 
Clinically Important Antimicrobial Resistance Patterns 
 
In the United States, fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) 
are commonly used to treat severe Salmonella infections, including typhoid and paratyphoid fever as well as 
severe nontyphoidal infections. In Enterobacteriaceae, (e.g., Salmonella and Shigella) resistance to nalidixic acid, 
an elementary quinolone, usually correlates with decreased susceptibility to ciprofloxacin (Table 2) and possible 
fluoroquinolone treatment failure, although sometimes resistance or decreased susceptibility to ciprofloxacin 
occurs in the absence of nalidixic acid resistance. Macrolides (e.g., azithromycin), penicillins (e.g., ampicillin), and 
trimethoprim-sulfamethoxazole are also of clinical importance. A substantial proportion of Enterobacteriaceae 
isolates tested in 2013 demonstrated clinically important resistance. 
 
In Salmonella, antimicrobial resistance varies by serotype. Overall changes in resistance among nontyphoidal 
Salmonella may reflect changes in resistance within serotypes, changes in serotype distribution, or both.   
 3% (61/2178) of nontyphoidal Salmonella isolates were resistant to nalidixic acid. Enteritidis was the most 
common serotype among nalidixic acid-resistant nontyphoidal Salmonella isolates.   
o 36% (22/61) of nalidixic acid-resistant isolates were ser. Enteritidis 
o 6% (22/382) of ser. Enteritidis isolates were resistant to nalidixic acid 
 3% (55/2178) of nontyphoidal Salmonella isolates were resistant to ceftriaxone. The most common serotypes 
among the 55 ceftriaxone-resistant isolates were Newport, Dublin, Typhimurium, Heidelberg, and Infantis. 
Resistance to ceftriaxone occurred in  
o 5% (11/209) of ser. Newport isolates 
o 92% (11/12) of ser. Dublin isolates 
o 3% (11/325) of ser. Typhimurium isolates 
o 15% (9/60) of ser. Heidelberg isolates 
o 7% (5/76) of ser. Infantis isolates 
 67% (188/279) of Salmonella ser. Typhi isolates were resistant to nalidixic acid, and 9% (24/279) were 
resistant to ciprofloxacin. 
 81% (81/100) of Salmonella ser. Paratyphi A isolates were resistant to nalidixic acid, and 4% (4/100) were 
resistant to ciprofloxacin. 
 No Salmonella ser. Typhi or Salmonella ser. Paratyphi A isolates were resistant to ceftriaxone. 
 
For Shigella, fluoroquinolones and macrolides (e.g., azithromycin) are important agents in the treatment of severe 
infections. (Note: Azithromycin breakpoints were established by NARMS for resistance monitoring and should not 
be used to predict clinical efficacy. CLSI has not established breakpoints for Shigella.)  
 3% (12/344) of Shigella isolates were resistant to ciprofloxacin, including 
o 6% (4/64) of Shigella flexneri isolates 
o 3% (8/275) of Shigella sonnei isolates 
 5% (12/344) of Shigella isolates were resistant to nalidixic acid, including 
o 13% (8/64) of Shigella flexneri isolates 
o 3% (9/275) of Shigella sonnei 
 4% (13/344) of Shigella isolates were resistant to azithromycin, including 
o 16% (10/64) of Shigella flexneri isolates 
o  1% (3/275) of Shigella sonnei isolates 
 
For Campylobacter, fluoroquinolones and macrolides are important treatment options for severe infections. 
ECOFF values are used for interpreting antimicrobial susceptibility data. Since ECOFFs differ between 
Campylobacter species, the percentage resistant for Campylobacter overall is not reported.  
Summary of NARMS 2013 Surveillance Data 
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 22% (263/1182) of Campylobacter jejuni isolates and 34% (45/134) of Campylobacter coli isolates were 
resistant to ciprofloxacin 
 2% (26/1182) of Campylobacter jejuni isolates and 17% (24/142) of Campylobacter coli isolates were 
resistant to erythromycin  
 2% (26/1182) of Campylobacter jejuni isolates and 18% (25/142) of Campylobacter coli isolates were 
resistant to azithromycin 
 
 
Multidrug Resistance 
 
Multidrug resistance is reported in NARMS in several ways, including resistance to various numbers of classes of 
antimicrobial agents and also by specific co-resistance phenotypes. 
 
For nontyphoidal Salmonella, an important multidrug-resistance phenotype includes resistance to at least 
ampicillin, chloramphenicol, streptomycin, sulfonamide (sulfamethoxazole/sulfisoxazole), and tetracycline 
(ACSSuT); these agents represent five CLSI classes. A similar pattern of resistance to at least ASSuT (but not 
chloramphenicol) has emerged in recent years. Another important phenotype includes resistance to at least 
ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone 
(ACSSuTAuCx); these agents represent seven CLSI classes.  
 3% (74/2178) of nontyphoidal Salmonella isolates were resistant to at least ACSSuT. The most common 
serotypes were Typhimurium, Newport, and Dublin.  ACSSuT resistance occurred in 
o 12% (39/325) ser. Typhimurium isolates 
o 5% (10/209) ser. Newport isolates 
o 83% (10/12) ser. Dublin isolates 
 
 3% (74/2178) of nontyphoidal Salmonella isolates were resistant to at least ASSuT but not chloramphenicol. 
The most common serotype was I 4,[5],12:i:- (59 isolates) followed by Typhimurium. This resistance pattern 
occurred in 
o 47% (59/127) ser. I 4,[5],12:i:- isolates 
o 1% (4/325) ser. Typhimurium isolates 
 
 1% (31/2178) of nontyphoidal Salmonella isolates were resistant to at least ACSSuTAuCx. The most common 
serotypes were Newport, Dublin, and Typhimurium.  This resistance pattern occurred in  
o 5% (10/209) ser. Newport isolates  
o 83% (10/12) ser. Dublin isolates 
o 2% (7/325) ser. Typhimurium isolates 
 
 10% (214/2178) of nontyphoidal Salmonella isolates were resistant to three or more CLSI classes. The most 
common serotypes with this resistance were I 4,[5],12:i:, Typhimurium, Heidelberg, Newport, Dublin, and 
Infantis. Resistance to three or more classes occurred in 
o 51% (65/127) ser. I 4,[5],12:i:- isolates  
o 17% (55/325) ser. Typhimurium isolates 
o 33% (20/60) ser. Heidelberg isolates 
o 6% (12/209) ser. Newport isolates  
o 92% (11/12) ser. Dublin isolates 
o 11% (8/76) ser. Infantis isolates 
 
For Salmonella ser. Typhi, an important multidrug-resistance phenotype includes resistance to at least ampicillin, 
chloramphenicol, and trimethoprim-sulfamethoxazole (ACT/S). 
 8% (23/279) of ser. Typhi isolates were resistant to at least ACT/S, and 10% (29/279) were resistant to three 
or more classes  
 
For Shigella, an important multidrug-resistance phenotype includes resistance to at least ampicillin and 
trimethoprim-sulfamethoxazole (AT/S). 
 26% (88/344) of Shigella isolates were resistant to at least AT/S, and 54% (184/344) were resistant to three 
or more classes 
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Changes in Antimicrobial Resistance: 2013 vs. 2004–2008 and 2008–2012 
 
To understand changes in the prevalence of antimicrobial resistance among Salmonella, Shigella, and Campylobacter over time, we 
used logistic regression to model annual data from 2004–2013. Since 2003, all 50 states have participated in Salmonella and Shigella 
surveillance, and all 10 FoodNet sites have participated in Campylobacter surveillance. We compared the prevalence of selected 
resistance patterns among isolates tested in 2013 with the average prevalence of resistance from two reference periods: 2004–2008 
and 2008–2012. (These methods are detailed in the Data Analysis section.) 
 
We defined the prevalence of resistance as the percentage of resistant isolates among the total isolates tested. Changes in the 
percentage of isolates that are resistant may not reflect changes in the incidence of resistant infections because of fluctuations in the 
incidence of illness caused by the pathogen or serotype from year to year. The incidence and relative changes in the incidence of 
Salmonella, Shigella, and Campylobacter infections are reported annually from surveillance in FoodNet sites (CDC, 2014). 
 
2013 vs. 2004–2008 
The differences between the prevalence of resistance in 2013 and the average prevalence of resistance in 2004–2008 (Figure H1, A) 
were statistically significant for the following:  
 
 Among Salmonella of particular serotypes  
o ACSSuT resistance in ser. Typhimurium was lower (12.0% vs. 22.3%; odds ratio [OR]=0.5, 95% confidence interval [CI] 
0.3–0.7)  
o Nalidixic acid resistance in ser. Typhi was higher (67.4% vs. 53.1%; OR=1.9, 95% CI 1.4–2.5)  
 
 Among Shigella spp.  
o Nalidixic acid resistance was higher (5.2% vs. 2.0%; OR=3.2, 95% CI 1.8–5.7).  
 
The differences between the prevalence of resistance in 2013 and the average prevalence of resistance in 2004–2008 (Figure H1, A) 
were not statistically significant for the following selected pathogen-resistance combinations: 
 
 Among nontyphoidal Salmonella  
o Ceftriaxone resistance (2.5% vs. 3.2%; OR=0.9, 95% CI 0.6–1.1)  
o Nalidixic acid resistance (2.8% vs. 2.2%; OR=1.4, 95% CI 1.0–1.9) 
o Resistance to one or more classes (19.2% vs. 18.7%; OR=1.1, 95% CI 1.0–1.2) 
o Resistance to three or more classes (9.8% vs. 11.2%; OR=0.9, 95% CI 0.8–1.1) 
 
  Among Salmonella of particular serotypes  
o Nalidixic acid resistance in ser. Enteritidis (5.8% vs. 6.3%; OR=1.0, 95% CI 0.6–1.5)  
o ACSSuTAuCx resistance in ser. Newport (4.8% vs. 11.7%; OR=0.5, 95% CI 0.3–1.1)  
o Ceftriaxone resistance in ser. Heidelberg (15.0% vs. 8.5%; OR=1.9, 95% CI 0.8–4.2) 
 
 Among Campylobacter jejuni and C. coli 
o Ciprofloxacin resistance in C. jejuni (22.3% vs. 21.6%; OR=1.1, 95% CI 0.9–1.3) 
o Ciprofloxacin resistance in C. coli (34.5% vs. 27.2%; OR=1.4, 95% CI 0.9–2.2)  
 
2013 vs. 2008–2012 
The differences between the prevalence of resistance in 2013 and the average prevalence of resistance in 2008–2012 (Figure H1, B) 
were statistically significant for the following:  
 
 Among nontyphoidal Salmonella  
o Resistance to one or more classes was higher (19.2% vs. 15.7%; OR=1.3, 95% CI 1.2–1.5)  
 
 Among Salmonella of particular serotypes  
o ACSSuT resistance in ser. Typhimurium was lower (12.0% vs. 19.7%;OR=0.6, 95% CI 0.4–0.8)  
   
The differences between the prevalence of resistance in 2013 and the average prevalence of resistance in 2008–2012 (Figure H1, B) 
were not statistically significant for the following selected pathogen-resistance combinations: 
 
 Among nontyphoidal Salmonella  
o Ceftriaxone resistance (2.5% vs. 2.9%; OR=0.9, 95% CI 0.7–1.2)  
o Nalidixic acid resistance (2.8% vs. 2.1%; OR=1.4, 95% CI 1.0–1.9) 
o Resistance to three or more classes (9.8% vs. 9.2%; OR=1.1, 95% CI 1.0–1.3) 
 
  Among Salmonella of particular serotypes  
o Nalidixic acid resistance in ser. Enteritidis (5.8% vs. 6.2%; OR=1.0, 95% CI 0.6–1.6)  
o ACSSuTAuCx resistance in ser. Newport (4.8% vs. 6.7%; OR=1.0, 95% CI 0.5–2.0)  
o Ceftriaxone resistance in ser. Heidelberg (15.0% vs. 16.7%; OR=0.9, 95% CI 0.4–2.0) 
o Nalidixic acid resistance in ser. Typhi (67.4% vs. 65.5%; OR=1.1, 95% CI 0.9–1.5) 
 
 Among Campylobacter jejuni and C. coli 
o Ciprofloxacin resistance in C. jejuni (22.3% vs. 23.4%; OR=1.0, 95% CI 0.8–1.1) 
o Ciprofloxacin resistance in C. coli (34.5% vs. 30.8%; OR=1.2, 95% CI 0.8–1.8)  
 
 Among Shigella spp. 
o Nalidixic acid resistance (5.2% vs. 3.8% (OR=1.7, 95% CI 1.0–2.9)   
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Changes in Antimicrobial Resistance: 2013 vs. 2004–2008 and 2008–2012 
Figure H1.  Changes in prevalence of selected resistance patterns among Salmonella, Shigella, and 
Campylobacter isolates, 2013 compared with 2004–2008 and 2008–2012* 
 
A. 2013 compared with 2004–2008* 
 
 
 
 
 
 
 
B. 2013 compared with 2008–2012* 
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Shigella¶ 
 
 
 
*    The prevalence of resistance in 2013 was compared with the average prevalence from two reference periods, 2004–2008 and 2008–2012.  
     Logistic regression models adjusted for site using a 9-level categorical variable (9 US census regions) for Salmonella and Shigella and 10- 
     level categorical variable (10 FoodNet states) for Campylobacter. The odds ratios (ORs) and 95% confidence intervals (CIs) were  
      calculated using unconditional maximum likelihood estimation. ORs that do not include 1.0 in the 95% CIs are reported as statistically significant.  
†   Antimicrobial classes of agents are those defined by the Clinical and Laboratory Standards Institute (CLSI) 
‡   ACSSuT: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline  
§   ACSSuTAuCx: resistance to at least ACSSuT,‡ amoxicillin-clavulanic acid, and ceftriaxone  
¶   For 2013 vs. 2008–2012, the main effects model was adjusted for site using a two-level categorical variable (East, West) 
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Increased Resistance to Macrolides in Campylobacter  
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Campylobacter is estimated to cause 1.3 million infections in the United States each year.1 Symptoms include 
diarrhea (often bloody), abdominal pain, and fever.2 Less common but more severe complications include 
extraintestinal infections, reactive arthritis, and Guillain-Barré syndrome.2 The primary antimicrobial treatment 
options for Campylobacter infection are fluoroquinolones and macrolides.2 Resistance to fluoroquinolones is 
common in the United States (24% in 2013) and elsewhere,3,4 at times leaving macrolides as the only treatment 
option.2 Historically, Campylobacter resistance to macrolides in the United States has been low (<5%), but 
increasing resistance to macrolides has been reported in many parts of the world.4 
 
In 2013, the percentage of human Campylobacter isolates with macrolide resistance increased. The change was 
small (from 1.8% in 2012 to 2.2% in 2013) among Campylobacter jejuni (Figure H2, A), the most common species 
isolated from humans, but larger among Campylobacter coli, increasing from 9.0% in 2012 to 17.6% in 2013 
(Figure H2, B). 
 
Macrolide resistance in Campylobacter is usually mediated by a mutation in one or more copies of the 
chromosomal 23S rRNA gene (Campylobacter has three copies of 23S). However, a new horizontally transferable 
resistance determinant, ermB, was recently identified among macrolide resistant Campylobacter coli. The ermB 
gene encodes an rRNA methylase and can be plasmid-encoded, allowing for rapid dissemination.5 Molecular 
studies are ongoing to identify the mechanism responsible for macrolide resistance among US Campylobacter 
isolates. 
 
 
Figure H2.  Percentage of Campylobacter isolates with resistance to macrolides*, 2004–2013 
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Increasing Non-Susceptibility to Quinolones among Nontyphoidal Salmonella  
 
Fluoroquinolones (e.g., ciprofloxacin), a subset of the quinolone antimicrobial class, are important therapeutic options 
for severe nontyphoidal Salmonella (NTS) infections, especially in adults.1 NARMS tests isolates of NTS for resistance 
to ciprofloxacin; a minimum inhibitory concentration (MIC) of 0.12–0.5 µg/mL is defined as intermediate, and MIC ≥1 
µg/mL is defined as resistant. The quinolone nalidixic acid is also tested; MIC ≥32 µg/mL is defined as resistant, and 
there is no intermediate category. Although nalidixic acid is not used to treat invasive salmonellosis, monitoring 
susceptibility to this drug is important for surveillance purposes. Resistance to nalidixic acid is correlated with non-
susceptibility to ciprofloxacin (intermediate or resistant) and may predict fluoroquinolone treatment failure.2  In NTS and 
other Enterobacteriaceae, a single point mutation in the quinolone resistance-determining region (QRDR) of 
topoisomerase usually leads to nalidixic acid resistance and reduced susceptibility to ciprofloxacin.3,4  Resistance to 
fluoroquinolones typically requires stepwise mutations in the QRDR that also result in nalidixic acid resistance. Non-
susceptibility to ciprofloxacin in absence of nalidixic acid resistance may indicate extra-chromosomal (non-QRDR), 
plasmid-mediated quinolone resistance (PMQR) mechanisms.4 
 
Non-susceptibility to quinolones has increased among NTS since 1996. Although both resistance to nalidixic acid and 
non-susceptibility to ciprofloxacin have been recently increasing, the trends diverged after 2005, with higher 
percentages of isolates with ciprofloxacin non-susceptibility than nalidixic acid resistance (Figure H3). From 2009 to 
2013, the percentage of isolates resistant to nalidixic acid increased from 1.8% (39/2193) to 2.8% (61/2178), while the 
percentage with non-susceptibility to ciprofloxacin increased from 2.4% (52/2193) to 3.5% (77/2178). Among NTS 
isolates with non-susceptibility to ciprofloxacin, the proportion that lacked nalidixic acid resistance was only 9.3% 
(24/258) during 1996–2005, compared with 24.8% (127/513) during 2006–2013. Testing of NTS isolates collected 
during 2004–20065 and 20074 showed an increase in the proportion of isolates harboring PMQR mechanisms compared 
with 1996–2003.6 NARMS is currently investigating the molecular mechanisms of resistance and possible sources of 
the more recent infections and undertaking analyses to describe correlations between nalidixic acid resistance and 
ciprofloxacin non-susceptibility in more detail at the serotype level. 
 
Figure H3.  Percentage of nontyphoidal Salmonella isolates with resistance to nalidixic acid compared 
with non-susceptibility to ciprofloxacin*, 1996–2013
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Continued Rise of ASSuT Resistance in Salmonella ser.  I 4,[5],12:i:-  
 
In 2013, the percentage of human Salmonella ser. I 4,[5],12:i:- isolates with resistance to ampicillin, streptomycin, sulfonamide, 
and tetracycline (ASSuT) but not chloramphenicol continued to increase. Resistance emerged in 2010 when the percentage of 
resistant isolates increased to nearly 17% from less than 1.5% for the previous 14 years.1 This resistance increased to 18.3% 
(15/82) in 2011, 26.5% (31/117) in 2012, and 45.5% (59/127) in 2013 (Figure H4).  
 
Serotype I 4,[5],12:i:- is a monophasic variant of serotype Typhimurium (I 4,[5],12:i:1,2). Resistance to ampicillin, streptomycin, 
sulfonamide, and tetracycline has also been observed among NARMS isolates of serotype Typhimurium; however, the 
majority of Typhimurium isolates resistant to these four agents have shown additional resistance to chloramphenicol. In 2013, 
90.7% (39/43) of Typhimurium isolates resistant to at least ASSuT were also chloramphenicol resistant (ACSSuT), compared 
with only 1.7% (1/60) of ASSuT I 4,[5],12:i:- isolates. Among all nontyphoidal Salmonella isolates tested by NARMS in 2013, 
74 (3.4%) were resistant to ASSuT but not chloramphenicol; 59 (79.7%) of these were serotype I 4,[5],12:i:-. The next most 
common serotype was Typhimurium with 4 (5.4%) isolates. (See the nontyphoidal Salmonella section for more detail). 
 
In Europe, a notable increase of Salmonella ser. I 4,[5],12:i:- infections with resistance to ASSuT but not chloramphenicol has 
been observed since the early 2000s, predating the emergence in the United States. The European emergence was caused 
by a clonal group of I 4,[5],12:i:- ASSuT strains commonly belonging to definitive phage type DT193, with resistance conferred 
by blaTEM-1, strA/B, sul2, and tet(B) genes on the chromosome.2,3  Similar to ACSSuT in DT104, ASSuT in DT193 is due to a 
Salmonella Genomic Island (SGI) located in the chromosome; however, the SGI type and location differ between the two 
strains. Exposure to pigs or pork products has frequently been reported in persons infected with the DT193 “European clone,” 
and the organism has been isolated from pigs.2 
 
In the United States, ASSuT-resistant serotype I 4,[5],12:i- with pulsed-field gel electrophoresis (PFGE) pattern JPXX01.1314 
(identical to DT193) and resistant determinates blaTEM-1, strA/B, sul2, and tet(B) has caused multiple outbreaks. Frequently, 
these events have been linked with animal exposure or consumption of pork or beef, including meats purchased from live 
animal markets.4  The increase of ASSuT-resistant serotype I 4,[5],12:i- in the United States is likely due to clonal expansion, 
given the frequency of the PFGE pattern and the resistance determinants likely being chromosomal, limiting horizontal 
transfer. These characteristics parallel the spread of DT193 in Europe.  
 
Figure H4.  Percentage of Salmonella ser. I 4,[5],12:i:- isolates with resistance to at least ASSuT* but not 
chloramphenicol, 2004–2013
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1. CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2011. Atlanta, Georgia: U.S. Department of Health and 
Human Services, CDC, 2013 
2. Hopkins KL, Kirchner M, Guerra B. Granier SA, Lucarelli C, Porrero MC, et al. Multiresistant Salmonella enterica serovar 4,[5],12:i:- in Europe: a new pandemic strain? Euro Surveill. 
2010;15(22):19580.  
3. Lucarelli C, Dionisi AM, Filetici E, Owczarek S, Luzzi I, Villa L. Nucleotide sequence of the chromosomal region conferring multidrug resistance (R-type ASSuT) in Salmonella 
Typhimurium and monophasic Salmonella Typhimurium strains. J Antimicrob Chemother. 2012;67(1):111–4. 
4. Imanishi M, Anderson TC, Routh J, Brown C, Conidi G, Glenn L, et al. Salmonellosis and meat purchased at live-bird and animal-slaughter markets, United States, 2007–2012. Emerg 
Infect Dis. 2014;20(1):167–9.
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Surveillance Sites and Isolate Submissions  
 
In 2013, NARMS conducted nationwide surveillance among the approximately 316 million persons living in the 
United States (2013 estimates published in the 2013 U.S. Census Bureau report). Public health laboratories 
systematically selected every 20th nontyphoidal Salmonella, Shigella, and Escherichia coli O157 isolate and every 
Salmonella ser. Typhi, Salmonella ser. Paratyphi A, and Salmonella ser. Paratyphi C isolate received at their 
laboratories and forwarded these isolates to CDC for antimicrobial susceptibility testing. With few exceptions, 
serotyping was performed at the public health laboratories and not further confirmed at CDC. Salmonella ser. 
Paratyphi B was included in the sampling for nontyphoidal Salmonella because laboratory methods are not 
always available to reliably distinguish between ser. Paratyphi B (which typically causes typhoidal illness) and ser. 
Paratyphi B var. L(+) tartrate+ (which does not typically cause typhoidal illness). Serotype Paratyphi B isolates for 
which the results of tartrate fermentation testing are reported as either “negative” or “missing” are retested and 
confirmed at CDC. Those identified as ser. Paratyphi B var. L(+) tartrate+ are included with other nontyphoidal 
Salmonella serotypes in this report. Because the number of ser. Paratyphi B (tartrate negative) and ser. Paratyphi 
C isolates is very small, this report includes susceptibility results only for ser. Paratyphi A.  
 
Beginning in 2009, NARMS performed susceptibility testing on isolates of Vibrio species other than V. cholerae 
submitted by the NARMS participating public health laboratories. Participants were asked to forward every Vibrio 
isolate that they received to CDC. Isolates of Vibrio species other than V. cholerae are confirmed in CDC’s 
National Enteric Reference Laboratory and tested for antimicrobial susceptibility by NARMS, whereas isolates of 
Vibrio cholerae are only characterized in the Reference Laboratory and not tested by NARMS. Due to an 
increasing number of Vibrio parahaemolyticus submissions, NARMS began selecting every other Vibrio 
parahaemolyticus isolate for antimicrobial susceptibility testing during 2013. NARMS continued to test every 
isolate of the remaining Vibrio species other than Vibrio cholerae. For information on toxigenic Vibrio cholerae, 
refer to the Cholera and Other Vibrio Illness Surveillance System (COVIS) annual summaries. 
 
Since 1997, NARMS has performed antimicrobial susceptibility testing on Campylobacter isolates submitted by 
the public health laboratories participating in CDC’s Foodborne Diseases Active Surveillance Network (FoodNet). 
The FoodNet sites, representing approximately 48 million persons (2013 estimates published in 2013 U.S. 
Census Bureau report), include Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, Tennessee, 
and selected counties in California, Colorado, and New York. From 1997 to 2004, public health laboratories then 
participating in FoodNet forwarded one Campylobacter isolate each week to CDC for susceptibility testing. In 
2005, a new scheme was introduced and sites began forwarding a sample of Campylobacter isolates based on 
the number of isolates received. They submitted every isolate (Georgia, Maryland, New Mexico, Oregon, and 
Tennessee), every other isolate (California, Colorado, Connecticut, and New York), or every fifth isolate 
(Minnesota) received. Starting in 2010, Georgia and Maryland submitted every other isolate received, and New 
Mexico submitted every third isolate received. State public health laboratories in FoodNet sites receive 
Campylobacter isolates from a convenience sample of reference and clinical laboratories in their state. Of the 
laboratories in each site that perform on-site testing for Campylobacter (range,19 to 101 per site in 2013), the 
number submitting isolates to the state public health laboratory ranged from one to 101 in 2013. 
 
 
 
 
 
 
  
Surveillance and Laboratory Testing Methods 
 23 
Table 1. Population size and number of isolates received and tested, 2013
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
4,833,722 (1.5) 66 (3.0) 6 (1.6) 15 (4.4) 0 (0) 0 (0)
735,132 (0.2) 3 (0.1) 5 (1.3) 1 (0.3) 0 (0) 2 (0.3)
6,626,624 (2.1) 54 (2.5) 13 (3.4) 0 (0) 4 (2.3) 2 (0.3)
2,959,373 (0.9) 30 (1.4) 0 (0) 10 (2.9) 1 (0.6) 0 (0)
28,315,453 (9) 54 (2.5) 40 (10.5) 0 (0) 10 (5.6) 74 (5.4) 30 (4.9)
5,268,367 (1.7) 33 (1.5) 5 (1.3) 6 (1.7) 3 (1.7) 28 (2.0) 10 (1.6)
3,596,080 (1.1) 25 (1.1) 7 (1.8) 3 (0.9) 1 (0.6) 158 (11.5) 25 (4.1)
925,749 (0.3) 8 (0.4) 3 (0.8) 1 (0.3) 1 (0.6) 2 (0.3)
646,449 (0.2) 9 (0.4) 1 (0.3) 2 (0.6) 0 (0) 0 (0)
19,552,860 (6.2) 76 (3.5) 12 (3.2) 6 (1.7) 0 (0) 124 (20.4)
9,992,167 (3.2) 125 (5.7) 11 (2.9) 45 (13.1) 2 (1.1) 193 (14.1) 14 (2.3)
1,404,054 (0.4) 9 (0.4) 2 (0.5) 3 (0.9) 3 (1.7) 25 (4.1)
2,195,914 (0.7) 48 (2.2) 5 (1.3) 31 (9) 0 (0) 0 (0)
1,612,136 (0.5) 8 (0.4) 2 (0.5) 1 (0.3) 2 (1.1) 0 (0)
12,882,135 (4.1) 105 (4.8) 24 (6.3) 17 (4.9) 10 (5.6) 1 (0.2)
6,570,902 (2.1) 39 (1.8) 4 (1.1) 2 (0.6) 6 (3.4) 4 (0.7)
3,090,416 (1) 23 (1.1) 2 (0.5) 1 (0.3) 4 (2.3) 7 (1.2)
2,893,957 (0.9) 15 (0.7) 1 (0.3) 2 (0.6) 2 (1.1) 0 (0)
4,395,295 (1.4) 20 (0.9) 2 (0.5) 0 (0) 2 (1.1) 1 (0.2)
10,017,068 (3.2) 56 (2.6) 18 (4.7) 2 (0.6) 1 (0.6) 0 (0)
4,625,470 (1.5) 49 (2.2) 0 (0) 12 (3.5) 0 (0) 21 (3.5)
1,328,302 (0.4) 4 (0.2) 0 (0) 1 (0.3) 3 (1.7) 7 (1.2)
5,928,814 (1.9) 47 (2.2) 15 (3.9) 4 (1.2) 5 (2.8) 249 (18.1) 24 (4)
6,692,824 (2.1) 77 (3.5) 20 (5.3) 11 (3.2) 3 (1.7) 47 (7.7)
9,895,622 (3.1) 44 (2.0) 3 (0.8) 6 (1.7) 0 (0) 4 (0.7)
5,420,380 (1.7) 40 (1.8) 6 (1.6) 7 (2) 8 (4.5) 166 (12.1) 13 (2.1)
2,991,207 (0.9) 46 (2.1) 0 (0) 8 (2.3) 1 (0.6) 7 (1.2)
6,044,171 (1.9) 61 (2.8) 1 (0.3) 7 (2) 14 (7.9) 2 (0.3)
1,015,165 (0.3) 9 (0.4) 0 (0) 4 (1.2) 6 (3.4) 2 (0.3)
1,868,516 (0.6) 11 (0.5) 0 (0) 8 (2.3) 4 (2.3) 2 (0.3)
2,790,136 (0.9) 17 (0.8) 1 (0.3) 0 (0) 1 (0.6) 2 (0.3)
1,323,459 (0.4) 9 (0.4) 3 (0.8) 0 (0) 0 (0) 3 (0.5)
8,899,339 (2.8) 49 (2.2) 25 (6.6) 7 (2) 6 (3.4) 22 (3.6)
2,085,287 (0.7) 21 (1.0) 1 (0.3) 2 (0.6) 0 (0) 90 (6.6) 1 (0.2)
11,245,290 (3.6) 71 (3.3) 13 (3.4) 4 (1.2) 5 (2.8) 196 (14.3) 35 (5.8)
8,405,837 (2.7) 62 (2.8) 39 (10.3) 15 (4.4) 4 (2.3) 12 (2)
9,848,060 (3.1) 91 (4.2) 9 (2.4) 5 (1.5) 1 (0.6) 4 (0.7)
723,393 (0.2) 6 (0.3) 0 (0) 2 (0.6) 1 (0.6) 1 (0.2)
11,570,808 (3.7) 65 (3.0) 9 (2.4) 8 (2.3) 7 (4.0) 3 (0.5)
3,850,568 (1.2) 33 (1.5) 1 (0.3) 2 (0.6) 6 (3.4) 0 (0)
3,930,065 (1.2) 21 (1.0) 4 (1.1) 4 (1.2) 7 (4.0) 145 (10.6) 7 (1.2)
12,773,801 (4) 75 (3.4) 12 (3.2) 6 (1.7) 6 (3.4) 2 (0.3)
1,051,511 (0.3) 8 (0.4) 1 (0.3) 8 (2.3) 0 (0) 10 (1.6)
4,774,839 (1.5) 54 (2.5) 0 (0) 4 (1.2) 1 (0.6) 7 (1.2)
844,877 (0.3) 9 (0.4) 0 (0) 2 (0.6) 1 (0.6) 0 (0)
6,495,978 (2.1) 44 (2.0) 3 (0.8) 27 (7.8) 4 (2.3) 73 (5.3) 3 (0.5)
24,252,279 (7.7) 153 (7.0) 11 (2.9) 10 (2.9) 4 (2.3) 32 (5.3)
2,900,872 (0.9) 16 (0.7) 2 (0.5) 1 (0.3) 2 (1.1) 1 (0.2)
626,630 (0.2) 4 (0.2) 0 (0) 1 (0.3) 1 (0.6) 0 (0)
8,260,405 (2.6) 52 (2.4) 14 (3.7) 4 (1.2) 1 (0.6) 21 (3.5)
6,971,406 (2.2) 34 (1.6) 20 (5.3) 7 (2) 11 (6.2) 62 (10.2)
1,854,304 (0.6) 35 (1.6) 0 (0) 5 (1.5) 5 (2.8) 0 (0)
5,742,713 (1.8) 50 (2.3) 4 (1.1) 2 (0.6) 5 (2.8) 3 (0.5)
582,658 (0.2) 5 (0.2) 0 (0) 2 (0.6) 2 (1.1) 0 (0)
316,128,839 (100) 2,178 (100) 380 (100) 344 (100) 177 (100) 1,372 (100) 607 (100)
*
†
‡
§
¶
**
††
‡‡
§§§§
State/Site
Colorado
California§ 
Campylobacter ‡
Vibrio species 
other than V. 
cholerae
Population Size*
Nontyphoidal
Salmonella
Typhoidal† 
Salmonella 
Shigella E. coli  O157
Alabama
Arizona
Alaska
Kansas
Iow a
Indiana
Illinois
Idaho
Houston, Texas¶
Haw aii
Georgia
Florida
District of Columbia
Delaw are
Connecticut
Arkansas
Tennessee
South Dakota
South Carolina
Rhode Island
Pennsylvania
Oregon
Oklahoma
Ohio
North Dakota
North Carolina
New  York City‡‡
New  York††
New  Mexico
Louisiana
Los Angeles**
Kentucky
Maryland
Maine
Texas§§
Utah
Minnesota
Michigan
Massachusetts
Nevada
Nebraska
Montana
Missouri
Mississippi
New  Jersey
New  Hampshire
Excluding Houston City
Wyoming
Total
Published in 2013 U.S. Census Bureau population estimates
Typhoidal Salmonella  includes serotypes Typhi, Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C. Because the number of ser. Paratyphi B (tartrate 
negative) and ser. Paratyphi C isolates is very small, susceptibility results for them are not reported.
Campylobacter  isolates are submitted only from FoodNet sites, w hich are Connecticut, Georgia, Maryland, Minnesota, New  Mexico, Oregon, Tennessee, and 
selected counties in California, Colorado, and New  York. Of the clinical laboratories in each site that perform on-site testing for Campylobacter  (range,19 to 101 per 
site in 2013), the number submitting isolates to the state public health laboratory ranged from one to all.
Excluding Los Angeles County
Houston City
Los Angeles County
Excluding New  York City
Five burroughs of New  York City (Bronx, Brooklyn, Manhattan, Queens, Staten Island)
xcl i  st , Texas
Vermont
Virginia
Washington
West Virginia
Wisconsin
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Testing of Salmonella, Shigella, and Escherichia coli O157  
 
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre®, Trek 
Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) according to manufacturer’s instructions to 
determine the MICs for each of 15 antimicrobial agents:  ampicillin, amoxicillin-clavulanic acid, azithromycin, 
cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table 2). Interpretive criteria 
defined by CLSI were used when available. Before 2004, sulfamethoxazole was used instead of sulfisoxazole to 
represent the sulfonamides. In 2011, azithromycin replaced amikacin on the panel of drugs tested for Salmonella, 
Shigella, and E. coli O157, so only historical susceptibility data are provided for amikacin. 
 
In January 2010, CLSI published revised interpretive criteria for ceftriaxone and Enterobacteriaceae; the revised 
resistance breakpoint for ceftriaxone is MIC ≥4 μg/mL. Since the 2009 report, NARMS has applied the revised 
CLSI breakpoint for ceftriaxone resistance to data from all years. In January 2012, CLSI published revised 
ciprofloxacin breakpoints for invasive Salmonella infections. For those infections, ciprofloxacin susceptibility is 
defined as ≤0.06 µg/mL; the intermediate category is defined as 0.12 to 0.5 µg/mL; and resistance is defined as 
≥1 µg/mL. In 2013, CLSI decided to apply these ciprofloxacin breakpoints to all subspecies and serotypes of 
Salmonella. In January 2014, CLSI added azithromycin MIC interpretive criteria for Salmonella ser. Typhi. 
Azithromycin susceptibility is defined as ≤16 µg/mL and resistance is defined as ≥32 µg/mL. These breakpoints 
match the NARMS-established breakpoints used for Enterobacteriaceae since azithromycin testing began in 
2011. In this report, NARMS continued to apply these breakpoints to MIC data for all Salmonella, Shigella, and E. 
coli O157 (Table 2). 
 
Repeat testing of isolates was done based on criteria in Appendix B. 
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Table 2.  Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia 
coli O157 isolates, 1996–2013 
CLSI Class Antimicrobial Agent Years Tested 
Antimicrobial Agent 
Concentration Range 
(g/mL) 
MIC Interpretive Standard (µg/mL) 
Susceptible 
Intermediate*/ 
S-DD† 
Resistant 
Aminoglycosides 
Amikacin 1997–2010 0.5–64 ≤16 32 ≥64 
Gentamicin all 0.25–16 ≤4 8 ≥16 
Kanamycin all 8–64 ≤16 32 ≥64 
Streptomycin‡ all 32–64 ≤32 N/A* ≥64 
β–lactam /  
β–lactamase  
inhibitor 
combinations 
Amoxicillin-clavulanic 
acid 
all 1/0.5–32/16 ≤8/4 16/8 ≥32/16 
Piperacillin-
tazobactam§ 
2011–present 0.5–128 ≤16/4 32/4–64/4 ≥128/4 
Cephems 
Cefepime†, § 2011–present 0.06–32 ≤2 4–8† ≥16 
Cefotaxime§ 2011–present 0.06–128 ≤1 2 ≥4 
Cefoxitin 2000–present 0.5–32 ≤8 16 ≥32 
Ceftazidime§ 2011–present 0.06–128 ≤4 8 ≥16 
Ceftiofur all 0.12–8 ≤2 4 ≥8 
Ceftriaxone¶ all 0.25–64 ≤1 2 ≥4 
Cephalothin†† 1996–2003 2–32 ≤8 16 ≥32 
Folate pathway 
inhibitors 
Sulfamethoxazole‡‡ 1996–2003 16–512 ≤256 N/A* ≥512 
Sulfisoxazole 2004–present 16–256 ≤256 N/A* ≥512 
Trimethoprim- 
sulfamethoxazole 
all 0.12/2.38–4/76 ≤2/38 N/A* ≥4/76 
Macrolides Azithromycin** 2011–present 0.12–16 ≤16 N/A* ≥32 
Monobactams Aztreonam§ 2011–present 0.06–32 ≤4 8 ≥16 
Penems Imipenem§ 2011–present 0.06–16 ≤1 2 ≥4 
Penicillins Ampicillin all 1–32 ≤8 16 ≥32 
Phenicols Chloramphenicol all 2–32 ≤8 16 ≥32 
Quinolones 
Ciprofloxacin 
 (Shigella and             
E. coli O157)  
all 0.015–4 ≤1 2 ≥4 
Ciprofloxacin††  
(Salmonella serotypes) 
all 0.015–4 ≤0.06 0.12–0.5 ≥1 
Nalidixic acid all 0.5–32 ≤16 N/A* ≥32 
Tetracyclines Tetracycline all 4–32 ≤4 8 ≥16 
 
*    N/A indicates that no MIC range of intermediate susceptibility exists 
†   Cefepime MICs above the susceptible range, but below the resistant range are now designated by CLSI to be susceptible-dose dependent   
     (S-DD) 
‡   CLSI breakpoints are not established for streptomycin; resistance breakpoint used in NARMS is ≥64 µg/mL 
§   Broad-spectrum β-lactam antimicrobial agent only tested for nontyphoidal Salmonella isolates displaying ceftriaxone       
     and/or ceftiofur resistance 
¶   CLSI updated the ceftriaxone interpretive standards in January, 2010. NARMS Human Isolate Reports for 1996 through        
     2008 used susceptible ≤8 µg/mL, intermediate 16-32 µg/mL, and resistant ≥64 µg/mL. 
**  CLSI breakpoints for azithromycin are only established for Salmonella ser. Typhi. The azithromycin breakpoints used elsewhere in this  
     report for nontyphi Salmonella, Shigella, and E.coli O157 isolates are NARMS-established breakpoints for resistance monitoring and  
     should not be used to predict clinical efficacy. 
†† CLSI updated the ciprofloxacin interpretive standards for Salmonella in January, 2012. NARMS Human Isolate Reports for 1996 through        
     2010 used susceptible ≤1 µg/mL, intermediate 2 µg/mL, and resistant ≥4 µg/mL. 
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Additional Testing of Salmonella Strains 
 
β-lactam Panel Testing 
Isolates displaying resistance to either ceftriaxone (MIC ≥4 μg/mL) or ceftiofur (MIC ≥8 μg/mL) on the Trek 
Sensititre® gram-negative panel were subsequently tested using broth microdilution on a Sensititre® β-lactam 
panel (Trek Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) according to manufacturer’s 
instructions. The panel contained additional broad-spectrum β-lactam drugs: aztreonam, cefepime, cefotaxime, 
ceftazidime, imipenem, and piperacillin-tazobactam (Table 2). Briefly, a suspension of each isolate was made in 
water to a McFarland standard equivalency of 0.5, 10uL of this suspension was then used to inoculate a 10mL 
tube of cation-adjusted Mueller-Hinton broth, 50uL of this inoculated broth was dosed into each well of the 96-well 
β-lactam panel plate, and results were read manually after 18-20 hours of incubation at 35°C. Quality control 
isolates for this testing were E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, and 
S. aureus ATCC 29213.  
 
Cephalosporin Retesting of Isolates from 1996–1998 
 
Some Salmonella isolates tested in NARMS during 1996 to 1998 had inconsistent cephalosporin susceptibility 
results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low 
ceftriaxone MIC, and some did not exhibit an elevated MIC to other β-lactams. Because these findings suggested 
that some previously reported results were inaccurate, isolates of Salmonella tested in NARMS during 1996 to 
1998 that exhibited an MIC ≥2 μg/mL to ceftiofur or ceftriaxone were retested using the 2003 NARMS Sensititre® 
plate. The retest results have been included in the NARMS annual reports since 2003. 
 
Serotype Confirmation/Categorization 
 
The Salmonella serotype reported by the submitting laboratory was used for reporting with few exceptions. The 
serotype was confirmed by CDC for isolates that underwent subsequent molecular analysis. Because of 
challenges in interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed for isolates 
reported as Salmonella ser. Paratyphi B by the submitting laboratory (ser. Paratyphi B is by definition unable to 
ferment L(+) tartrate). To distinguish Salmonella ser. Paratyphi B and ser. Paratyphi B var. L(+) tartrate+ (formerly 
ser. Java), CDC performed Jordan’s tartrate test or Kauffmann’s tartrate test or both tests on all Salmonella ser. 
Paratyphi B isolates for which the tartrate result was not reported or was reported to be negative. Isolates 
negative for tartrate fermentation by all assays conducted were categorized as ser. Paratyphi B; as noted above, 
because the number of ser. Paratyphi B (tartrate negative) is very small, this report does not include susceptibility 
results for this serotype.  Isolates that were positive for tartrate fermentation by either assay were categorized as 
ser. Paratyphi B var. L(+) tartrate+ and were included with other nontyphoidal Salmonella in this report. CDC did 
not confirm other biochemical reactions or somatic and flagellar antigens. 
 
Because of increased submissions of Salmonella ser. I 4,[5],12:i:- noted in previous years and recognition of the 
possibility that this serotype may have been underreported in previous years, antigen results provided for isolates 
reported only as serogroup B and tested in NARMS during 1996 to 2012 were reviewed; isolates that could be 
clearly identified as serogroup B, first-phase flagellar antigen “i,” second phase flagellar antigen absent, were 
categorized as Salmonella ser. I 4,[5],12:i:-. 
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Testing of Campylobacter 
 
Changes in Identification/Speciation and Antimicrobial Susceptibility Testing Over Time 
 
From 2003 to 2004, Campylobacter isolates were identified as C. jejuni or C. coli using BAX® System PCR Assay 
according to the manufacturer's instructions (DuPont, Wilmington, DE). Isolates not identified as C. jejuni or C. 
coli were further characterized by other PCR assays (Linton et al. 1996) or were characterized by the CDC 
National Campylobacter Reference Laboratory. From 1997 to 2002, methodology similar to that used from 2005 
to 2009 was used. 
 
From 2005 to 2010, isolates were confirmed as Campylobacter by determination of typical morphology and 
motility using dark-field microscopy and a positive oxidase test reaction. Identification of C. jejuni was performed 
using the hippurate hydrolysis test. Hippurate-positive isolates were identified as C. jejuni. Hippurate-negative 
isolates were further characterized with PCR assays with specific targets for C. jejuni (mapA or hipO gene), C. 
coli-specific ceuE gene (Linton et al. 1997, Gonzales et al. 1997, Pruckler et al. 2006), or other species-specific 
primers. In 2010, all C. jejuni and suspected C. coli isolates were also confirmed through a multiplex PCR 
(Vandamme et al. 1997). In 2010 and 2011, the ceuE PCR was not used, and all C. jejuni and suspected C. coli 
isolates were confirmed through a multiplex PCR (Vandamme et al. 1997). From 2012 to present, all genus-
confirmed Campylobacter isolates were identified at the species level through a combination of multiplex PCR, 
biochemical tests, and other species-specific PCRs as needed. 
 
The methods for susceptibility testing of Campylobacter and criteria for interpreting the results have also changed 
during the course of NARMS surveillance. From 1997 to 2004, Etest® (AB bioMerieux, Solna, Sweden) was used 
for susceptibility testing of Campylobacter isolates. Campylobacter-specific CLSI interpretive criteria were used 
for erythromycin, ciprofloxacin, and tetracycline beginning with the 2004 NARMS annual report.  NARMS 
breakpoints were used for agents for which CLSI breakpoints were not available. Beginning in 2004, NARMS 
breakpoints were established based on the MIC distributions of NARMS isolates and the presence of known 
resistance genes or mutations. In pre-2004 annual reports, NARMS breakpoints used had been based on those 
available for other organisms. Establishment of breakpoints based on MIC distributions resulted in higher MIC 
breakpoints for azithromycin and erythromycin resistance compared with those reported in pre-2004 annual 
reports. Beginning in 2005, broth microdilution using the Sensititre® system (Trek Diagnostics, part of Thermo 
Fisher Scientific, Cleveland, OH) was performed according to manufacturer’s instructions to determine the MICs 
for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, erythromycin, florfenicol, gentamicin, 
nalidixic acid, telithromycin, and tetracycline (Table 3). CLSI recommendations for quality control were followed. 
The interpretive criteria listed in Table 3 have been applied to MIC data collected for all years so that resistance 
prevalence is comparable over time. In 2012, the criteria for interpretation of results were changed from the 
previously used breakpoints to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
epidemiological cut-off values (ECOFFs). Repeat testing of isolates was based on criteria in Appendix B. 
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Table 3.  Antimicrobial agents used for susceptibility testing of Campylobacter isolates, 1997–2013 
CLSI Class 
Antimicrobial 
Agent 
Years Tested 
Antimicrobial 
Agent 
Concentration 
Range (µg/mL) 
MIC Interpretive Standard (µg/mL)† 
C. jejuni C. coli 
Susceptible Resistant Susceptible Resistant 
Aminoglycosides Gentamicin 1998–present 
0.12–32 
0.016–256* 
≤2 ≥4 ≤2 ≥4 
Ketolides Telithromycin 2005–present 0.015–8 ≤4 ≥8 4 ≥8 
Lincosamides Clindamycin all 
0.03–16 
0.016–256* 
≤0.5 ≥1 ≤1 ≥2 
Macrolides 
Azithromycin 1998–present 
0.015–64 
0.016–256* 
≤0.25 ≥0.5 ≤0.5 ≥1 
Erythromycin all 
0.03–64 
0.016–256* 
≤4 ≥8 ≤8 ≥16 
Phenicols 
Chloramphenicol 1997–2004 0.016–256* ≤16 ≥32 ≤16 ≥32 
Florfenicol 2005–present 0.03–64 ≤4 ≥8 ≤4 ≥8 
Quinolones 
Ciprofloxacin all 
0.015–64 
0.002–32* 
≤0.5 ≥1 ≤0.5 ≥1 
Nalidixic acid all 
4–64 
0.016–256* 
≤16 ≥32 ≤16 ≥32 
Tetracyclines Tetracycline all 
0.06–64 
0.016–256* 
≤1 ≥2 ≤2 ≥4 
 
*  Etest dilution range used from 1997–2004 
† MIC interpretative standard is based on epidemiological cut-off values established by the European Committee on Antimicrobial    
   Susceptibility Testing (EUCAST). This approach was adopted in 2012 and applied to all years. EUCAST uses the terms “wild type”   
   and “non-wild type” instead of susceptible and resistant, respectively, to reflect the nature of the populations of bacteria in each group and to  
   highlight that these categories are not to be used to predict clinical efficacy. 
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Testing of Vibrio species other than V. cholerae 
 
NARMS participating public health laboratories were asked to forward every Vibrio isolate that they received to 
CDC. Isolates of Vibrio species other than V. cholerae are confirmed in CDC’s National Enteric Reference 
Laboratory and tested for antimicrobial susceptibility by NARMS, whereas isolates of Vibrio cholerae are only 
characterized in the Reference Laboratory and not tested by NARMS. Due to an increasing number of Vibrio 
parahaemolyticus submissions, NARMS began selecting every other Vibrio parahaemolyticus isolate for 
antimicrobial susceptibility testing during 2013. NARMS continued to test every isolate of the remaining Vibrio 
species other than Vibrio cholerae.   
 
Minimum inhibitory concentrations were determined by Etest® (AB bioMerieux, Solna, Sweden) according to 
manufacturer’s instructions for ten antimicrobial agents: ampicillin, cefotaxime, ceftazidime, chloramphenicol, 
ciprofloxacin, gentamicin, imipenem, nalidixic acid, tetracycline, and trimethoprim-sulfamethoxazole (Table 4). In 
2013, cefotaxime, ceftazidime, gentamicin, and imipenem were added to the panel of drugs tested, while 
cephalothin, kanamycin, and streptomycin were removed. CLSI breakpoints specific for Vibrio species other than 
V. cholerae were available for ampicillin, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, 
tetracycline, and trimethoprim-sulfamethoxazole. The percentage of isolates susceptible, intermediate, and 
resistant to those agents in 2013 is shown in this report (Table 58). MIC distributions are shown for all agents 
tested in 2013. Historical resistance data are shown for ampicillin only, as resistance to the other tested drugs is 
extremely low. For information on toxigenic Vibrio cholerae, refer to the Cholera and Other Vibrio Illness 
Surveillance System (COVIS) annual summaries. 
 
Table 4.  Antimicrobial agents used for susceptibility testing of Vibrio species other than V. cholerae 
isolates, 2009–2013 
CLSI Class 
Antimicrobial 
Agent 
Years Tested 
Antimicrobial Agent 
Concentration Range 
(g/mL) 
MIC Interpretive Standard (µg/mL) 
Susceptible Intermediate* Resistant 
Aminoglycosides 
Gentamicin 2013 0.064–1024 ≤4 8 ≥16 
Kanamycin 2009–2012 0.015–256 No CLSI or NARMS breakpoints 
Streptomycin 2009–2012 0.064–1024 No CLSI or NARMS breakpoints 
Cephems 
Cefotaxime 2013 0.016–256 ≤1 2 ≥4 
Ceftazidime 2013 0.016–256 ≤4 8 ≥16 
Cephalothin 2009–2012 0.015–256  No CLSI or NARMS breakpoints 
Folate pathway 
inhibitors 
Trimethoprim- 
sulfamethoxazole 
all 0.002–32 ≤2/38 N/A ≥4/76 
Penems Imipenem 2013 0.002–32 ≤4 8 ≥16 
Penicillins Ampicillin all 0.015–256 ≤8 16 ≥32 
Phenicols Chloramphenicol all 0.015–256 No CLSI or NARMS breakpoints 
Quinolones 
Ciprofloxacin all 0.002–32 ≤1 2 ≥4 
Nalidixic acid all 0.015–256 No CLSI or NARMS breakpoints 
Tetracyclines Tetracycline all 0.015–256 ≤4 8 ≥16 
 
*  N/A indicates that no MIC range of intermediate susceptibility exists 
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Data Analysis 
 
For all pathogens, isolates were categorized as resistant, intermediate (if applicable), or susceptible. For 
Campylobacter, epidemiological cutoff values established by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) were used to interpret MICs. This approach assigns bacteria to one of two 
groups: wild type or non-wild type. For simplicity, the EUCAST wild type and non-wild type are referred to in this 
report as susceptible and resistant, respectively.  
 
Analysis was restricted to the first isolate received per patient in the calendar year (per serotype for Salmonella, 
per species for Campylobacter, Shigella, and Vibrio species other than Vibrio cholerae). If two or more Salmonella 
ser. Typhi isolates were received for the same patient, the first blood isolate, or other isolate from a normally 
sterile site collected, was included in the analysis.  If no blood isolate or other isolate from a normally sterile site 
was submitted, the first isolate collected was included in analysis. The 95% confidence intervals (CIs) for the 
percentage resistant, which were calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson 
exact method, are included in the MIC distribution tables.  
 
In the analysis of antimicrobial class resistance among Salmonella, Shigella, and E. coli O157, nine CLSI 
classes (Table 2) were represented by the following agents: amoxicillin-clavulanic acid, ampicillin, 
azithromycin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic 
acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. Isolates 
that were not resistant to any of these agents were considered to have no resistance detected. In the analysis 
of antimicrobial class resistance among Campylobacter, seven CLSI classes were represented by 
azithromycin, ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, gentamicin, nalidixic acid, 
telithromycin, and tetracycline (Table 3). Campylobacter isolates that were not resistant to any of these agents 
were considered to have no resistance detected. 
 
Using logistic regression, we modelled annual data from 2004–2013 to assess changes in the prevalence of 
antimicrobial resistance among Salmonella, Shigella, and Campylobacter isolates. We compared the prevalence 
of resistance among isolates tested in 2013 with the average prevalence from two reference periods, 2004–2008 
and the previous five years, 2008–2012. The 2004–2008 reference period begins with the second year that all 50 
states participated in Salmonella and Shigella surveillance and all 10 FoodNet sites participated in NARMS 
Campylobacter surveillance. The additional 2008–2012 reference period allows for comparisons with more recent 
years. We defined the prevalence of resistance as the percentage of resistant isolates among the total number of 
isolates tested. Changes in the percentage of isolates that are resistant may not reflect changes in the incidence 
of resistant infections because of fluctuations in the incidence of illness caused by the pathogen or serotype from 
year to year. The incidence and relative changes in the incidence of Salmonella, Shigella, and Campylobacter 
infections are reported annually from surveillance in FoodNet sites (CDC, 2014). Comparisons were made for the 
following:  
 
 Nontyphoidal Salmonella: resistance to nalidixic acid, ceftriaxone, one or more CLSI classes, three or more 
CLSI classes 
 Salmonella of particular serotypes 
o Salmonella ser. Enteritidis: resistance to nalidixic acid 
o Salmonella ser. Typhimurium: resistance to at least ACSSuT (ampicillin, chloramphenicol, 
streptomycin, sulfonamide, and tetracycline) 
o Salmonella ser. Newport: resistance to at least ACSSuTAuCx (ACSSuT, amoxicillin-clavulanic acid, 
and ceftriaxone) 
o Salmonella ser. Heidelberg resistance to ceftriaxone  
o Salmonella ser. Typhi: resistance to nalidixic acid 
 Shigella: resistance to nalidixic acid 
 Campylobacter jejuni, C. coli: resistance to ciprofloxacin  
 
In the logistic regression analysis for main effects, year was modelled as a 10-level categorical variable. To 
account for site-to-site variation in the prevalence of antimicrobial resistance, we included adjustments for site. 
The final regression models for Salmonella and Shigella adjusted for the submitting site using the nine division 
categories described by the U.S. Census Bureau: East North Central, East South Central, Middle Atlantic, 
Mountain, New England, Pacific, South Atlantic, West North Central, and West South Central. For 
Campylobacter, the final regression models adjusted for the submitting site using the 10 FoodNet states. Odds 
ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional maximum likelihood  
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estimation. The adequacy of model fit was assessed in several ways (Fleiss et al., 2004; Kleinbaum et al., 2008). 
The significance of the main effect of year was assessed using the likelihood ratio test. The likelihood ratio test 
was also used to test for significance of interaction between site and year, although the power of the test to detect 
a single site-specific interaction was low. When the main effect of year was significant, we report ORs with 95% 
CIs (for 2013 compared with 2004-2008 and 2008–2012) that did not include 1.0 as statistically significant. 
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MIC Distribution Tables and Proportional Figures 
 
An explanation of “how to read a squashtogram” has been provided to assist the reader with the table (Figure 1). 
A squashtogram shows the distribution of MICs for antimicrobial agents tested. Proportional figures visually 
display data from squashtograms for an immediate comparative summary of resistance in specific pathogens and 
serotypes. These figures are a visual aid for the interpretation of MIC values. For most antimicrobial agents 
tested, three categories (susceptible, intermediate, and resistant) are used to interpret MICs. The proportion 
representing each category is shown in a horizontal proportional bar chart (Figure 2). 
 
Figure 1.  How to read a squashtogram 
 
 
  
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.2] 7.4 70.1 20.8 1.6 0.1
Gentamicin 0.1 2.1 [1.5–2.8] 53.5 41.4 2.8 0.1 0.1 0.9 1.2
Streptomycin N/A 10.4 [9.1–11.7] 89.6 4.4 6.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 4.2 3.3 [2.6–4.1] 84.8 4.9 0.4 2.5 4.2 0.6 2.7
Cephems Ceftiofur 0.0 3.2 [2.6–4.1] 0.3 0.8 27.5 66.7 1.4 0.1 3.1
Ceftriaxone 2.3 0.4 [0.2–0.8] 96.7 0.1 0.5 1.4 0.9 0.3 0.1
Penicillins Ampicillin 0.0 10.1 [8.9–11.5] 81.2 8.3 0.3 0.1 0.1 10.0
Quinolones Ciprofloxacin 0.0 0.1 [0.0–0.3] 92.9 4.4 0.2 1.3 0.8 0.3 0.1
Nalidixic acid N/A 2.2 [1.7–3.0] 0.1 0.2 34.4 61.9 0.9 0.2 2.2
Aminoglycosides Kanamycin < 0.1 2.8 [2.2–3.6] 96.8 0.2 < 0.1 0.2 2.6
Cephems Cefoxitin 0.7 3.0 [2.3–3.7] 0.2 8.8 70.2 15.8 1.3 0.7 0.9 2.1
Folate pathway inhibitors Sulfisoxazole N/A 12.3 [11.0–13.8] 19.0 53.1 15.0 0.5 0.1 12.3
Trimethoprim-sulfamethoxazole N/A 1.6 [1.1–2.2] 79.7 18.3 0.2 0.2 0.1 1.5
Phenicols Chloramphenicol 0.7 7.3 [6.2–8.5] 0.8 41.7 49.5 0.7 0.4 6.9
Tetracyclines Tetracycline 0.1 14.5 [13.0–16.0] 85.4 0.1 0.9 4.2 9.4
CLSI† Antimicrobial Class Antimicrobial Agent
II
Percent of all isolates with MIC (µg/mL)**% of isolates
Rank *
I
Critically important 
antimicrobial agents
Highly important 
antimicrobial agents
Percent with
Intermediate result
Percent 
resistant
95% confidence interval 
for percent resistant
Sum of percents = 
% susceptible
Sum of percents = 
% intermediate
Sum of percents = 
% resistant
Single line is upper limit of 
susceptibility / lower limit of 
intermediate result
Double line is upper limit of 
intermediate result / lower limit 
of full resistance 
MIC value
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Figure 2.  Proportional chart, a categorical graph of a squashtogram 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin <0.1 1.7 [1.2 - 2.3] 8.3 76.4 13.1 0.5 <0.1 0.2 1.5
Kanamycin <0.1 1.7 [1.2 - 2.3] 98.2 0.1 <0.1 <0.1 1.6
Streptomycin N/A 9.8 [8.6 - 11.1] 90.2 2.3 7.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 2.0 2.6 [2.0 - 3.3] 89.2 1.7 0.6 3.9 2.0 0.8 1.8
Cephems Ceftiofur <0.1 2.5 [1.9 - 3.2] 0.3 0.8 37.7 57.7 1.0 <0.1 0.2 2.3
Ceftriaxone <0.1 2.5 [1.9 - 3.2] 97.5 <0.1 0.1 0.3 1.0 0.8 0.3 0.1
Macrolide Azithromycin N/A 0.2 [0.1 - 0.5] 0.2 0.4 11.2 80.4 7.3 0.2 0.2
Penicillins Ampicillin 0.1 9.1 [8.0 - 10.3] 86.9 3.5 0.3 0.1 0.1 0.2 8.9
Quinolones Ciprofloxacin 2.8 0.2 [0.0 - 0.4] 91.9 4.9 0.2 1.0 0.9 0.9 0.1 0.1
Nalidixic acid N/A 2.4 [1.8 - 3.1] 0.2 0.6 47.4 48.1 0.9 0.4 0.1 2.3
Cephems Cefoxitin 0.2 2.6 [2.0 - 3.3] 0.4 31.1 53.7 10.7 1.3 0.2 1.1 1.5
Folate pathway inhibitors Sulfisoxazole N/A 8.6 [7.5 - 9.8] 5.9 46.1 37.8 1.5 8.6
Trimethoprim-sulfamethoxazole N/A 1.2 [0.8 - 1.7] 96.8 1.7 0.2 <0.1 <0.1 1.2
Phenicols Chloramphenicol 0.6 4.4 [3.6 - 5.3] 0.9 51.0 43.1 0.6 0.1 4.3
Tetracyclines Tetracycline 0.2 10.5 [9.2 - 11.8] 89.4 0.2 0.3 1.9 8.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL) **
 
 
 
Gentamicin 
Kanamycin 
Streptomycin 
Amoxicillin-clavulanic acid 
Ceftiofur 
Ceftriaxone 
Azithromycin 
Ampicillin 
Ciprofloxacin 
Nalidixic acid 
Cefoxitin 
Sulfisoxazole 
Trimethoprim-sulfamethoxazole 
Chloramphenicol 
Tetracycline 
Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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1.  Nontyphoidal Salmonella 
 
Table 5.  Number of nontyphoidal Salmonella isolates of the most common serotypes* tested with the number of resistant isolates by class and agent, 
2013 
N (%) 0 1 2–3 4–5 6–7 8 GEN KAN STR AMC FOX TIO AXO FIS COT AZI AMP CHL CIP NAL TET
382 (17.5) 334 31 11 5 1 0 0 0 10 0 0 1 1 6 2 0 22 1 0 22 17
325 (14.9) 226 25 26 40 8 0 4 1 67 11 11 11 11 68 4 0 54 44 0 5 69
209 (9.6) 192 5 2 0 10 0 1 1 12 11 11 11 11 10 1 0 13 10 0 0 13
140 (6.4) 126 12 2 0 0 0 0 0 6 1 0 0 0 0 0 0 1 0 0 4 4
127 (5.8) 50 8 7 60 2 0 6 1 68 2 2 2 2 68 3 2 63 3 1 1 70
76 (3.5) 62 5 5 1 3 0 3 3 3 3 3 5 5 7 3 0 7 3 0 4 10
60 (2.8) 28 1 26 4 1 0 13 16 24 8 9 9 9 9 1 0 20 4 0 0 20
59 (2.7) 58 0 1 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1
56 (2.6) 44 6 6 0 0 0 3 0 5 0 0 0 0 4 1 0 4 0 0 2 7
53 (2.4) 51 2 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0
44 (2.0) 44 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
36 (1.7) 35 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
34 (1.6) 30 2 2 0 0 0 1 0 1 0 1 0 0 1 0 0 2 0 0 1 0
33 (1.5) 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
28 (1.3) 23 2 1 1 0 1 1 2 2 1 1 1 1 3 2 0 2 2 0 2 4
28 (1.3) 22 4 0 2 0 0 0 0 2 0 0 0 0 2 0 0 2 3 1 3 2
20 (0.9) 19 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
19 (0.9) 16 1 2 0 0 0 0 0 1 0 0 0 0 2 1 0 0 0 0 0 2
17 (0.8) 17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
16 (0.7) 13 2 1 0 0 0 0 0 1 1 1 1 1 0 0 0 1 0 0 0 1
15 (0.7) 13 0 2 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 2 0 2
15 (0.7) 12 2 1 0 0 0 0 0 2 0 0 0 0 1 0 0 0 0 0 0 1
14 (0.6) 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
13 (0.6) 9 3 1 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 2
12 (0.6) 1 0 0 0 10 1 2 8 10 11 10 11 11 11 1 0 11 11 0 1 11
11 (0.5) 2 0 9 0 0 0 0 0 9 0 0 0 0 0 0 0 1 0 0 0 9
11 (0.5) 10 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
11 (0.5) 10 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
10 (0.5) 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 (0.5) 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1884 (86.5) 1514 115 105 113 35 2 34 32 228 49 49 52 52 196 22 2 203 81 4 49 245
All other serotypes 239 (11.0) 203 12 12 8 4 0 6 1 15 3 2 2 2 23 8 1 16 4 5 9 25
Partially serotyped 13 (0.6) 11 0 1 1 0 0 1 2 2 0 1 0 0 1 0 1 1 0 1 1 1
6 (0.3) 4 1 0 1 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 0
36 (1.7) 28 2 3 3 0 0 2 0 5 1 1 1 1 4 0 0 6 0 1 1 4
2178 (100) 1760 130 121 126 39 2 43 35 251 53 53 55 55 225 31 5 227 85 11 61 275
*
†
‡
Quinolones Tetracyclines
Number of Isolates Number of Resistant Isolates by CLSI
†
 Antimicrobial Class and Agent
‡
Folate 
pathway 
inhibitors
Macrolides PenicillinsNumber of CLSI
†
 Antimicrobial 
Classes to which Isolates are 
Resistant
Aminoglycosides
β-lactam/β-
lactamase 
inhibitor 
combinations
Cephems Phenicols
Isolates
Only serotypes with at least 10 isolates are listed individually
CLSI: Clinical and Laboratory Standards Institute
Antimicrobial agent abbreviations: GEN, gentamicin; KAN, kanamycin; STR, streptomycin; AMC, amoxicillin-clavulanic acid; FOX, cefoxitin; TIO, ceftiofur; AXO, ceftriaxone; FIS, sulfisoxazole; COT, trimethoprim-sulfamethoxazole; AZI, azithromycin; 
AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; NAL, nalidixic acid; TET, tetracycline
Rough/Nonmotile isolates
Unknown serotype
Paratyphi B var. L(+) tartrate+
Anatum
Bareilly
Poona
Berta
Litchfield
Subtotal
Schwarzengrund
Rubislaw
Total
Mbandaka
Dublin
Hadar
Panama
Hartford
Sandiego
Uganda
Serotype*
Enteritidis
Typhimurium
Newport
Muenchen
Thompson
Agona
Javiana
I 4,[5],12:i:-
Infantis
Heidelberg
Oranienburg
Saintpaul
Montevideo
Braenderup
Mississippi
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Table 6.  Percentage and number of nontyphoidal Salmonella isolates with selected resistance patterns, 
by serotype, 2013 
N n (%) n (%) n (%) n (%) n (%) n (%)
Twenty most common serotypes
1 Enteritidis 382 1 (1.4) 0 (0) 0 (0) 22 (36.1) 1 (1.8) 1 (20.0)
2 Typhimurium 325 39 (52.7) 0 (0) 7 (22.6) 5 (8.2) 11 (20.0) 0 (0)
3 Newport 209 10 (13.5) 1 (10.0) 10 (32.3) 0 (0) 11 (20.0) 0 (0)
4 Javiana 140 0 (0) 0 (0) 0 (0) 4 (6.6) 0 (0) 0 (0)
5 I 4,[5],12:i:- 127 1 (1.4) 1 (10.0) 0 (0) 1 (1.6) 2 (3.6) 0 (0)
6 Infantis 76 1 (1.4) 1 (10.0) 1 (3.2) 4 (6.6) 5 (9.1) 2 (40.0)
7 Heidelberg 60 4 (5.4) 1 (10.0) 1 (3.2) 0 (0) 9 (16.4) 0 (0)
8 Muenchen 59 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
9 Saintpaul 56 0 (0) 0 (0) 0 (0) 2 (3.3) 0 (0) 0 (0)
10 Montevideo 53 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
11 Braenderup 44 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
12 Mississippi 36 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
13 Oranienburg 34 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
14 Thompson 33 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
15 Agona 28 2 (2.7) 2 (20.0) 1 (3.2) 2 (3.3) 1 (1.8) 1 (20.0)
Paratyphi B var. L(+) tartrate+ 28 2 (2.7) 0 (0) 0 (0) 3 (4.9) 0 (0) 0 (0)
17 Anatum 20 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
18 Bareilly 19 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
19 Poona 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
20 Berta 16 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0)
Mbandaka 13 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
Dublin 12 10 (13.5) 1 (10.0) 10 (32.3) 1 (1.6) 11 (20.0) 1 (20.0)
Uganda 11 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
Senftenberg 7 1 (1.4) 1 (10.0) 1 (3.2) 0 (0) 1 (1.8) 0 (0)
Kentucky 6 0 (0) 0 (0) 0 (0) 3 (4.9) 1 (1.8) 0 (0)
Muenster 6 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
Bredeney 4 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
Choleraesuis 2 2 (2.7) 2 (20.0) 0 (0) 2 (3.3) 0 (0) 0 (0)
Indiana 2 1 (1.4) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
London 2 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
1827 74 (100) 10 (100) 31 (100) 58 (95.1) 54 (98.2) 5 (100)
All other serotypes 296 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Partially serotyped 13 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
Rough/Nonmotile isolates 6 0 (0) 0 (0) 0 (0) 1 (1.6) 0 (0) 0 (0)
Unknown serotype 36 0 (0) 0 (0) 0 (0) 1 (1.6) 1 (1.8) 0 (0)
2178 74 (100) 10 (100) 31 (100) 61 (100) 55 (100) 5 (100)
*
†
‡
§
¶
Additional serotypes
¶
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, and ceftriaxone
CxN: resistance to ceftriaxone and nalidixic acid
Additional serotypes that displayed resistance to at least one of the selected patterns
Subtotal
Total
At least 
ACSSuT*
At least   
ACT/S
†
At least 
ACSSuTAuCx
‡
Nalidixic Acid Ceftriaxone
 At least      
CxN
§
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Table 7.  Percentage and number of nontyphoidal Salmonella isolates with resistance, by number of CLSI* 
classes and serotype, 2013 
N n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Enteritidis 382 6 (2.8) 6 (3.6) 1 (1.1) 1 (2.4) 1 (2.9) 0 (0) 0 -
Typhimurium 325 55 (25.7) 48 (28.7) 40 (46.0) 8 (19.5) 7 (20.0) 0 (0) 0 -
Newport 209 12 (5.6) 10 (6.0) 10 (11.5) 10 (24.4) 10 (28.6) 0 (0) 0 -
Javiana 140 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
I 4,[5],12:i:- 127 65 (30.4) 62 (37.1) 3 (3.4) 2 (4.9) 1 (2.9) 0 (0) 0 -
Infantis 76 8 (3.7) 4 (2.4) 4 (4.6) 3 (7.3) 2 (5.7) 0 (0) 0 -
Heidelberg 60 20 (9.3) 5 (3.0) 4 (4.6) 1 (2.4) 1 (2.9) 0 (0) 0 -
Muenchen 59 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Saintpaul 56 4 (1.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Montevideo 53 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Braenderup 44 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Mississippi 36 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Oranienburg 34 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Thompson 33 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Agona 28 2 (0.9) 2 (1.2) 2 (2.3) 1 (2.4) 1 (2.9) 1 (50.0) 0 -
Paratyphi B var. L(+) tartrate+ 28 2 (0.9) 2 (1.2) 2 (2.3) 0 (0) 0 (0) 0 (0) 0 -
Anatum 20 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Bareilly 19 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Poona 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Berta 16 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Litchfield 15 2 (0.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Dublin 12 11 (5.1) 11 (6.6) 11 (12.6) 11 (26.8) 11 (31.4) 1 (50.0) 0 -
Hadar 11 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Senftenberg 7 1 (0.5) 1 (0.6) 1 (1.1) 1 (2.4) 1 (2.9) 0 (0) 0 -
Kentucky 6 4 (1.9) 3 (1.8) 2 (2.3) 0 (0) 0 (0) 0 (0) 0 -
Brandenburg 5 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Derby 5 2 (0.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Bredeney 4 1 (0.5) 1 (0.6) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 -
Lomalinda 4 1 (0.5) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Choleraesuis 2 2 (0.9) 2 (1.2) 2 (2.3) 2 (4.9) 0 (0) 0 (0) 0 -
Indiana 2 1 (0.5) 1 (0.6) 1 (1.1) 1 (2.4) 0 (0) 0 (0) 0 -
London 2 1 (0.5) 1 (0.6) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 -
IIIb 48:i:z 1 1 (0.5) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Reading 1 1 (0.5) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
1839 206 (96.3) 162 (97) 85 (97.7) 41 (100) 35 (100) 2 (100) 0 -
All other serotypes 284 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Partially serotyped 13 2 (0.9) 1 (0.6) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 -
Rough/Nonmotile isolates 6 1 (0.5) 1 (0.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 -
Unknown serotype 36 5 (2.3) 3 (1.8) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 -
2178 214 (100) 167 (100) 87 (100) 41 (100) 35 (100) 2 (100) 0 -
* CLSI: Clinical and Laboratory Standards Institute
† Additional serotypes that displayed resistance to at least three CLSI classes
≥ 8 CLSI classes*
17
11
12
13
14
6
7
8
9
10
≥ 6 CLSI classes*≥ 3 CLSI classes* ≥ 7 CLSI classes*
1
2
3
4
15
≥ 4 CLSI classes* ≥ 5 CLSI classes*
Subtotal
Total
18
19
Additional serotypes
†
20
≥ 9 CLSI classes*
5
Twenty most common serotypes
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Table 8.  Minimum inhibitory concentrations (MICs) and resistance of nontyphoidal Salmonella isolates to 
antimicrobial agents, 2013 (N=2178) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin <0.1 2.0 [1.4 - 2.7] 11.6 77.5 8.3 0.6 0.1 <0.1 0.6 1.4
Kanamycin 0.1 1.6 [1.1 - 2.2] 98.0 0.2 0.1 0.2 1.4
Streptomycin N/A 11.5 [10.2 - 12.9] 88.5 3.0 8.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 2.6 2.4 [1.8 - 3.2] 84.2 3.9 1.7 5.2 2.6 0.1 2.3
Cephems Ceftiofur 0.1 2.5 [1.9 - 3.3] 0.1 0.2 13.3 81.7 2.1 0.1 0.1 2.4
Ceftriaxone <0.1 2.5 [1.9 - 3.3] 97.2 0.1 <0.1 <0.1 0.2 1.1 1.0 0.2 <0.1
Macrolide Azithromycin N/A 0.2 [0.1 - 0.5] <0.1 <0.1 0.1 2.8 82.8 13.3 0.6 0.2
Penicillins Ampicillin 0.0 10.4 [9.2 - 11.8] 81.1 7.2 0.9 0.4 0.1 10.3
Quinolones Ciprofloxacin 3.0 0.5 [0.3 - 0.9] 83.0 13.1 0.4 1.0 1.1 0.9 0.1 0.1 0.3
Nalidixic acid N/A 2.8 [2.1 - 3.6] <0.1 0.1 30.3 64.6 1.2 0.9 0.5 2.3
Cephems Cefoxitin 0.4 2.4 [1.8 - 3.2] 0.1 5.9 72.0 17.9 1.3 0.4 0.7 1.7
Folate pathway inhibitors Sulfisoxazole N/A 10.3 [9.1 - 11.7] 10.8 56.2 21.7 0.6 0.4 10.3
Trimethoprim-sulfamethoxazole N/A 1.4 [1.0 - 2.0] 95.7 2.4 0.3 <0.1 0.1 0.2 1.2
Phenicols Chloramphenicol 0.9 3.9 [3.1 - 4.8] 0.5 37.3 57.3 0.9 <0.1 3.9
Tetracyclines Tetracycline 1.0 12.6 [11.3 - 14.1] 86.4 1.0 0.2 2.1 10.4
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
 
Figure 3.  Antimicrobial resistance pattern for nontyphoidal Salmonella, 2013 
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Table 9.  Percentage and number of nontyphoidal Salmonella isolates resistant to antimicrobial agents, 
2004–2013 
2004
1782
2005
2036
2006
2171
2007
2145
2008
2384
2009
2193
2010
2449
2011
2335
2012
2233
2013
2178
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
< 0.1% 
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
1.3%
24
2.2%
44
2.0%
44
2.1%
45
1.5%
35
1.3%
28
1.0%
24
1.7%
40
1.2%
26
2.0%
43
Kanamycin
(MIC ≥ 64)
2.8%
50
3.4%
70
2.9%
63
2.8%
61
2.1%
50
2.5%
54
2.2%
54
1.7%
39
1.1%
24
1.6%
35
Streptomycin
(MIC ≥ 64)
12.0%
213
11.1%
225
10.7%
233
10.3%
222
10.0%
238
8.9%
196
8.6%
210
9.8%
229
8.4%
187
11.5%
251
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
3.7%
66
3.2%
65
3.7%
81
3.3%
70
3.1%
73
3.4%
75
2.9%
70
2.6%
60
2.9%
65
2.4%
53
Ceftiofur
(MIC ≥ 8)
3.4%
60
2.9%
59
3.6%
79
3.3%
70
3.1%
73
3.4%
75
2.8%
69
2.5%
58
2.9%
64
2.5%
55
Ceftriaxone
(MIC ≥ 4)
3.3%
59
2.9%
59
3.7%
80
3.3%
70
3.1%
73
3.4%
75
2.9%
70
2.5%
58
2.9%
64
2.5%
55
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.2%
5
< 0.1% 
1
0.2%
5
Penicillins Ampicillin
(MIC ≥ 32)
12.1%
216
11.3%
231
10.9%
237
10.1%
217
9.7%
232
9.8%
216
9.1%
223
9.1%
213
8.8%
196
10.4%
227
Ciprofloxacin
(MIC ≥ 1)
0.3%
5
0.1% 
2
0.1%
3
0.1% 
2
0.2%
5
0.3%
7
0.2%
6
0.2%
4
0.3%
7
0.5%
11
Nalidixic Acid
(MIC ≥ 32)
2.2%
39
1.9%
38
2.4%
52
2.2%
48
2.1%
49
1.8%
39
2.0%
48
2.2%
51
2.4%
54
2.8%
61
Cephems Cefoxitin
(MIC ≥ 32)
3.4%
61
3.0%
62
3.5%
77
2.9%
63
3.0%
72
3.2%
71
2.6%
63
2.6%
60
2.7%
61
2.4%
53
Sulfisoxazole
(MIC ≥ 512)
13.3%
237
12.6%
256
12.1%
263
12.3%
264
10.1%
240
9.9%
217
9.0%
221
8.6%
201
8.4%
188
10.3%
225
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
1.7%
31
1.7%
34
1.7%
36
1.5%
33
1.6%
37
1.7%
38
1.6%
38
1.2%
28
1.3%
29
1.4%
31
Phenicols Chloramphenicol
(MIC ≥ 32)
7.6%
136
7.8%
159
6.4%
139
7.3%
156
6.1%
146
5.7%
125
5.0%
122
4.4%
103
3.9%
87
3.9%
85
Tetracyclines Tetracycline
(MIC ≥ 16)
13.6%
242
13.9%
282
13.5%
293
14.5%
310
11.5%
275
11.9%
261
11.0%
270
10.5%
245
11.1%
247
12.6%
275
*
†
Year
Total Isolates
Rank*
I
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Aminoglycosides
Cephems
Quinolones
Folate pathway inhibitors
II
 
 
Table 10.  Resistance patterns of nontyphoidal Salmonella isolates, 2004–2013 
2004
1782
2005
2036
2006
2171
2007
2145
2008
2384
2009
2193
2010
2449
2011
2335
2012
2233
2013
2178
79.9%
1424
80.9%
1648
80.5%
1748
81.1%
1739
83.9%
2000
83.2%
1824
84.6%
2073
84.8%
1981
84.7%
1892
80.8%
1760
20.1%
358
19.1%
388
19.5%
423
18.9%
406
16.1%
384
16.8%
369
15.4%
376
15.2%
354
15.3%
341
19.2%
418
15.0%
267
14.8%
301
14.7%
320
14.2%
305
12.5%
298
13.0%
284
11.3%
276
11.1%
259
11.8%
264
13.2%
288
11.4%
204
11.9%
243
11.8%
256
11.1%
239
9.6%
228
9.6%
211
9.2%
225
9.1%
213
8.6%
193
9.8%
214
9.3%
165
9.1%
185
8.2%
177
8.2%
176
7.4%
177
7.3%
159
6.8%
166
6.5%
152
6.1%
137
7.7%
167
8.0%
142
7.2%
146
6.3%
137
6.9%
149
6.6%
157
6.2%
137
5.2%
128
4.6%
108
3.9%
88
4.0%
87
7.2%
129
6.9%
141
5.6%
121
6.3%
136
5.8%
138
5.1%
112
4.4%
107
3.9%
91
3.4%
77
3.4%
74
1.1%
19
0.8%
16
1.0%
22
0.8%
17
0.7%
17
0.6%
14
1.7%
42
1.8%
42
2.0%
44
3.4%
74
0.6%
10
0.9%
18
0.7%
15
0.7%
16
0.5%
11
0.7%
15
0.4%
11
0.4%
9
0.3%
7
0.5%
10
2.4%
42
2.0%
41
2.0%
43
2.1%
46
1.8%
44
1.4%
30
1.3%
33
1.5%
36
1.5%
34
1.4%
31
3.3%
59
2.9%
59
3.6%
78
3.0%
65
2.9%
69
3.3%
73
2.5%
62
2.5%
58
2.8%
62
2.3%
51
0.1%
2
< 0.1%
1
0.2%
4
0.2%
5
< 0.1%
1
0.2%
4
0.1%
2
0.1%
2
0.3%
6
0.2%
5
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.1%
2
0.0%
0
0.1%
3
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
< 0.1%
1
0.0%
0
0.0%
0
*
†
‡
§
¶
**
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
At least ASSuT‡ and not resistant to 
chloramphenicol
At least AAuCx**
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ACT/S§
At least ACSSuTAuCx¶
At least ceftriaxone and nalidixic acid 
resistant
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Table 11.  Broad-Spectrum β-lactam resistance among all ceftriaxone or ceftiofur resistant nontyphoidal 
Salmonella isolates, 2011 (N=58), 2012 (N=64), and 2013 (N=55) 
% I‡ (or S-DD§) %R¶ [95% CI]** 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
β-lactam / β-lactamase 
inhibitor combinations
Piperacillin-
tazobactam
2011 (58) 15.5 10.3 [3.9 - 21.2] 1.7 5.2 15.5 39.7 12.1 5.2 10.3 3.4 6.9
2012 (64) 9.4 6.3 [1.7 - 15.2] 3.1 12.5 56.3 12.5 7.8 1.6 3.1 3.1
2013 (55) 10.9 1.8 [0.0 - 9.7] 5.5 25.5 40.0 16.4 3.6 7.3 1.8
Cephems Cefepime§ 2011 (58) (1.7§) 1.7 [0.0 - 9.2] 3.4 32.8 41.4 13.8 5.2 1.7§ 1.7
2012 (64) (4.7§) 0.0 [0.0 - 5.6] 1.6 12.5 56.3 17.2 7.8 1.6§ 3.1§
2013 (55) (3.6§) 1.8 [0.0 - 9.7] 3.6 16.4 58.2 10.9 5.5 1.8§ 1.8§ 1.8
Cefotaxime 2011 (58) 0.0 100 [93.8 - 100] 1.7 10.3 37.9 34.5 10.3 3.4 1.7
2012 (64) 0.0 100 [94.4 - 100] 3.1 4.7 50.0 34.4 4.7 1.6 1.6
2013 (55) 0.0 100 [93.5 - 100] 1.8 10.9 43.6 36.4 5.5 1.8
Ceftazidime 2011 (58) 3.4 96.6 [88.1 - 99.6] 3.4 22.4 53.4 12.1 6.9 1.7
2012 (64) 4.7 90.6 [80.7 - 96.5] 4.7 4.7 40.6 37.5 9.4 3.1
2013 (55) 5.5 89.1 [77.8 - 95.9] 3.6 1.8 5.5 25.5 47.3 16.4
Monobactams Aztreonam 2011 (58) 43.1 41.4 [28.6 - 55.1] 6.9 8.6 43.1 27.6 8.6 5.2
2012 (64) 56.3 28.1 [17.6 - 40.8] 1.6 1.6 12.5 56.3 18.8 7.8 1.6
2013 (55) 43.6 32.7 [20.7 - 46.7] 3.6 20.0 43.6 21.8 9.1 1.8
Penems Imipenem 2011 (58) 0.0 1.7 [0.0 - 9.2] 1.7 77.6 19.0 1.7
2012 (64) 0.0 0.0 [0.0 - 5.6] 3.1 56.3 40.6
2013 (55) 0.0 0.0 [0.0 - 6.5] 1.8 7.3 87.3 3.6
*
†
‡
§
¶
**
††
Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility
Percentage of isolates that are susceptible-dose dependent (S-DD). Cefepime MICs above the susceptible range but below  the resistant range are now  designated by CLSI to be S-DD. Corresponding dilution ranges are 
shaded in orange.
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method
The unshaded and orange-shaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Orange-shaded areas also indicate the dilution range for susceptible-dose dependent (S-DD). Single vertical 
bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the gray shaded areas indicate the percentages of isolates w ith MICs greater than the highest 
concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used 
w hen available.
Year (# of isolates)
I
Rank*
CLSI† Antimicrobial 
Class
Antimicrobial 
Agent
Percentage of isolates Percentage of all isolates w ith MIC (µg/mL)††
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A. Salmonella ser. Enteritidis 
 
Table 12.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Enteritidis isolates 
to antimicrobial agents, 2013 (N=382) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.0] 38.0 59.4 2.4 0.3
Kanamycin 0.0 0.0 [0.0 - 1.0] 100.0
Streptomycin N/A 2.6 [1.3 - 4.8] 97.4 1.0 1.6
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.8 0.0 [0.0 - 1.0] 89.0 2.9 1.3 6.0 0.8
Cephems Ceftiofur 0.0 0.3 [0.0 - 1.4] 1.8 94.8 3.1 0.3
Ceftriaxone 0.0 0.3 [0.0 - 1.4] 99.7 0.3
Macrolide Azithromycin N/A 0.0 [0.0 - 1.0] 0.3 2.1 90.8 6.3 0.5
Penicillins Ampicillin 0.0 5.8 [3.6 - 8.6] 75.4 16.8 1.6 0.5 5.8
Quinolones Ciprofloxacin 5.8 0.0 [0.0 - 1.0] 47.6 46.6 2.6 2.9 0.3
Nalidixic acid N/A 5.8 [3.6 - 8.6] 11.3 80.6 2.1 0.3 0.3 5.5
Cephems Cefoxitin 0.3 0.0 [0.0 - 1.0] 1.8 84.6 11.8 1.6 0.3
Folate pathway inhibitors Sulfisoxazole N/A 1.6 [0.6 - 3.4] 6.8 73.8 17.0 0.8 1.6
Trimethoprim-sulfamethoxazole N/A 0.5 [0.1 - 1.9] 98.2 0.8 0.5 0.3 0.3
Phenicols Chloramphenicol 0.8 0.3 [0.0 - 1.4] 1.0 41.9 56.0 0.8 0.3
Tetracyclines Tetracycline 0.5 4.5 [2.6 - 7.0] 95.0 0.5 1.0 3.4
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 4.  Antimicrobial resistance pattern for Salmonella ser. Enteritidis, 2013 
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Table 13.  Percentage and number of Salmonella ser. Enteritidis isolates resistant to antimicrobial agents, 
2004–2013 
2004
271
2005
384
2006
412
2007
385
2008
442
2009
410
2010
513
2011
391
2012
364
2013
382
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.4%
1
0.8%
3
0.2%
1
0.0%
0
0.2%
1
0.0%
0
0.2%
1
0.5%
2
0.0%
0
0.0%
0
Kanamycin
(MIC ≥ 64)
0.7%
2
0.3%
1
0.2%
1
0.5%
2
0.0%
0
0.2%
1
0.2%
1
0.3%
1
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
2.2%
6
1.0%
4
1.2%
5
0.5%
2
0.7%
3
1.2%
5
0.6%
3
1.8%
7
1.9%
7
2.6%
10
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.8%
3
0.5%
2
0.5%
2
0.0%
0
0.0%
0
0.4%
2
0.3%
1
0.5%
2
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.3%
1
0.5%
2
0.3%
1
0.2%
1
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.3%
1
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.3%
1
0.5%
2
0.3%
1
0.2%
1
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.3%
1
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
4.1%
11
2.6%
10
4.1%
17
2.1%
8
4.1%
18
3.9%
16
2.3%
12
5.1%
20
4.1%
15
5.8%
22
Ciprofloxacin
(MIC ≥ 1)
0.4%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.0%
0
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
6.6%
18
4.7%
18
7.0%
29
5.7%
22
7.2%
32
3.7%
15
5.3%
27
7.2%
28
7.7%
28
5.8%
22
Cephems Cefoxitin
(MIC ≥ 32)
0.0%
0
1.0%
4
0.5%
2
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.0%
0
Sulfisoxazole
(MIC ≥ 512)
1.8%
5
1.6%
6
1.5%
6
1.6%
6
1.4%
6
1.7%
7
1.9%
10
2.0%
8
2.7%
10
1.6%
6
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.0%
0
0.5%
2
0.5%
2
1.0%
4
0.9%
4
0.7%
3
1.0%
5
0.5%
2
1.1%
4
0.5%
2
Phenicols Chloramphenicol
(MIC ≥ 32)
0.4%
1
0.5%
2
0.0%
0
0.5%
2
0.5%
2
0.0%
0
0.6%
3
0.0%
0
0.5%
2
0.3%
1
Tetracyclines Tetracycline
(MIC ≥ 16)
3.3%
9
2.3%
9
1.7%
7
3.9%
15
1.8%
8
1.2%
5
2.1%
11
1.8%
7
3.6%
13
4.5%
17
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 14.  Resistance patterns of Salmonella ser. Enteritidis isolates, 2004–2013
2004
271
2005
384
2006
412
2007
385
2008
442
2009
410
2010
513
2011
391
2012
364
2013
382
86.7%
235
91.4%
351
88.8%
366
90.4%
348
87.3%
386
92.0%
377
92.0%
472
88.0%
344
88.2%
321
87.4%
334
13.3%
36
8.6%
33
11.2%
46
9.6%
37
12.7%
56
8.0%
33
8.0%
41
12.0%
47
11.8%
43
12.6%
48
3.0%
8
3.4%
13
2.9%
12
3.4%
13
2.3%
10
2.4%
10
2.9%
15
2.6%
10
4.9%
18
4.5%
17
1.1%
3
1.3%
5
1.7%
7
1.0%
4
0.7%
3
1.0%
4
2.1%
11
2.3%
9
2.7%
10
1.6%
6
0.7%
2
1.0%
4
0.7%
3
0.3%
1
0.2%
1
0.5%
2
0.4%
2
1.3%
5
1.6%
6
1.6%
6
0.7%
2
0.5%
2
0.2%
1
0.3%
1
0.0%
0
0.2%
1
0.0%
0
0.5%
2
0.5%
2
0.3%
1
0.4%
1
0.5%
2
0.0%
0
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.4%
1
0.0%
0
0.2%
1
0.0%
0
0.0%
0
0.2%
1
0.4%
2
1.3%
5
1.1%
4
0.8%
3
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.0%
0
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.2%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
Year
Total Isolates
Resistance Pattern
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
At least AAuCx**
At least ceftriaxone and nalidixic acid 
resistant
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
  
 B. Salmonella ser. Typhimurium 
42 
 
Table 15.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhimurium 
isolates to antimicrobial agents, 2013 (N=325) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 1.2 [0.3 - 3.1] 4.0 83.7 10.5 0.6 0.3 0.9
Kanamycin 0.0 0.3 [0.0 - 1.7] 99.1 0.6 0.3
Streptomycin N/A 20.6 [16.3 - 25.4] 79.4 6.5 14.2
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 10.8 3.4 [1.7 - 6.0] 77.5 4.0 1.5 2.8 10.8 3.4
Cephems Ceftiofur 0.0 3.4 [1.7 - 6.0] 0.6 0.6 8.0 86.5 0.9 0.3 3.1
Ceftriaxone 0.0 3.4 [1.7 - 6.0] 96.6 1.2 1.5 0.6
Macrolide Azithromycin N/A 0.0 [0.0 - 1.1] 0.3 0.3 1.8 92.3 5.2
Penicillins Ampicillin 0.0 16.6 [12.7 - 21.1] 76.0 6.5 0.9 16.6
Quinolones Ciprofloxacin 2.5 0.0 [0.0 - 1.1] 93.8 3.1 0.6 0.9 0.6 0.9
Nalidixic acid N/A 1.5 [0.5 - 3.6] 0.3 0.6 29.5 67.1 0.3 0.6 1.5
Cephems Cefoxitin 0.0 3.4 [1.7 - 6.0] 5.2 82.2 7.7 1.5 1.8 1.5
Folate pathway inhibitors Sulfisoxazole N/A 20.9 [16.6 - 25.8] 8.0 62.2 8.0 0.9 20.9
Trimethoprim-sulfamethoxazole N/A 1.2 [0.3 - 3.1] 92.9 5.5 0.3 0.3 0.9
Phenicols Chloramphenicol 0.0 13.5 [10.0 - 17.7] 1.2 31.7 53.5 0.3 13.2
Tetracyclines Tetracycline 1.2 21.2 [16.9 - 26.1] 77.5 1.2 0.9 8.6 11.7
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 5.  Antimicrobial resistance pattern for Salmonella ser. Typhimurium, 2013
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Table 16.  Percentage and number of Salmonella ser. Typhimurium isolates resistant to antimicrobial 
agents, 2004–2013 
2004
382
2005
438
2006
408
2007
405
2008
396
2009
370
2010
359
2011
323
2012
296
2013
325
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
2.1%
8
1.8%
8
2.7%
11
2.5%
10
1.5%
6
1.9%
7
0.8%
3
1.9%
6
3.0%
9
1.2%
4
Kanamycin
(MIC ≥ 64)
5.8%
22
5.7%
25
5.1%
21
5.9%
24
2.5%
10
4.9%
18
7.2%
26
4.0%
13
2.0%
6
0.3%
1
Streptomycin
(MIC ≥ 64)
31.9%
122
28.1%
123
29.4%
120
32.3%
131
28.5%
113
25.9%
96
25.6%
92
25.7%
83
24.0%
71
20.6%
67
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
4.7%
18
3.2%
14
4.4%
18
6.7%
27
3.5%
14
6.2%
23
4.2%
15
7.1%
23
5.7%
17
3.4%
11
Ceftiofur
(MIC ≥ 8)
4.5%
17
2.5%
11
4.2%
17
6.4%
26
3.5%
14
6.5%
24
4.7%
17
6.8%
22
5.7%
17
3.4%
11
Ceftriaxone
(MIC ≥ 4)
4.5%
17
2.5%
11
4.2%
17
6.4%
26
3.5%
14
6.5%
24
4.7%
17
6.8%
22
5.7%
17
3.4%
11
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
32.2%
123
29.0%
127
28.2%
115
31.6%
128
26.3%
104
28.1%
104
26.2%
94
26.0%
84
23.6%
70
16.6%
54
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.2%
1
0.2%
1
0.0%
0
0.0%
0
0.8%
3
0.0%
0
0.0%
0
0.3%
1
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
0.5%
2
0.9%
4
0.7%
3
1.5%
6
1.0%
4
2.2%
8
1.4%
5
0.3%
1
1.7%
5
1.5%
5
Cephems Cefoxitin
(MIC ≥ 32)
4.7%
18
2.5%
11
3.9%
16
5.7%
23
3.5%
14
5.4%
20
3.3%
12
6.8%
22
5.4%
16
3.4%
11
Sulfisoxazole
(MIC ≥ 512)
36.1%
138
32.0%
140
33.3%
136
37.3%
151
30.3%
120
30.0%
111
28.7%
103
27.2%
88
27.0%
80
20.9%
68
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
2.6%
10
2.7%
12
2.2%
9
2.5%
10
1.8%
7
3.0%
11
1.9%
7
1.9%
6
1.7%
5
1.2%
4
Phenicols Chloramphenicol
(MIC ≥ 32)
24.3%
93
24.4%
107
22.1%
90
25.4%
103
23.5%
93
20.5%
76
20.3%
73
19.8%
64
18.2%
54
13.5%
44
Tetracyclines Tetracycline
(MIC ≥ 16)
30.4%
116
30.4%
133
31.6%
129
36.8%
149
27.8%
110
28.9%
107
29.0%
104
27.2%
88
27.0%
80
21.2%
69
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 17.  Resistance patterns of Salmonella ser. Typhimurium isolates, 2004–2013 
2004
382
2005
438
2006
408
2007
405
2008
396
2009
370
2010
359
2011
323
2012
296
2013
325
60.5%
231
65.1%
285
62.5%
255
57.5%
233
67.9%
269
63.5%
235
66.9%
240
69.0%
223
68.6%
203
69.5%
226
39.5%
151
34.9%
153
37.5%
153
42.5%
172
32.1%
127
36.5%
135
33.1%
119
31.0%
100
31.4%
93
30.5%
99
37.2%
142
33.3%
146
34.1%
139
39.3%
159
31.3%
124
33.2%
123
30.4%
109
28.8%
93
29.4%
87
22.8%
74
31.7%
121
30.1%
132
30.4%
124
34.3%
139
27.8%
110
28.1%
104
27.3%
98
26.3%
85
24.7%
73
16.9%
55
27.7%
106
27.4%
120
27.0%
110
29.9%
121
24.7%
98
24.1%
89
24.2%
87
22.0%
71
20.9%
62
14.8%
48
24.3%
93
22.8%
100
20.8%
85
24.9%
101
24.0%
95
22.2%
82
20.9%
75
21.1%
68
18.6%
55
12.3%
40
23.6%
90
22.4%
98
19.6%
80
22.7%
92
23.2%
92
19.5%
72
18.7%
67
19.8%
64
17.2%
51
12.0%
39
2.4%
9
2.3%
10
3.2%
13
3.7%
15
0.3%
1
1.6%
6
3.6%
13
1.2%
4
1.7%
5
1.2%
4
1.6%
6
2.1%
9
0.7%
3
2.0%
8
0.5%
2
2.2%
8
1.1%
4
0.6%
2
0.7%
2
0.0%
0
2.6%
10
1.8%
8
2.9%
12
3.7%
15
2.3%
9
1.6%
6
1.7%
6
5.3%
17
4.1%
12
2.2%
7
4.5%
17
2.5%
11
4.2%
17
6.2%
25
3.5%
14
6.2%
23
3.6%
13
6.8%
22
5.7%
17
3.4%
11
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.0%
0
0.5%
2
0.3%
1
0.0%
0
0.7%
2
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
At least AAuCx**
  
 C. Salmonella ser. Newport 
44 
 
Table 18.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Newport isolates 
to antimicrobial agents, 2013 (N=209) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.5 [0.0 - 2.6] 4.3 86.1 8.6 0.5 0.5
Kanamycin 0.0 0.5 [0.0 - 2.6] 99.0 0.5 0.5
Streptomycin N/A 5.7 [3.0 - 9.8] 94.3 1.0 4.8
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 5.3 [2.7 - 9.2] 88.5 3.3 1.9 1.0 0.5 4.8
Cephems Ceftiofur 0.0 5.3 [2.7 - 9.2] 6.2 88.0 0.5 5.3
Ceftriaxone 0.0 5.3 [2.7 - 9.2] 94.7 1.9 3.3
Macrolide Azithromycin N/A 0.0 [0.0 - 1.7] 2.9 92.8 3.8 0.5
Penicillins Ampicillin 0.0 6.2 [3.4 - 10.4] 90.0 3.8 0.5 5.7
Quinolones Ciprofloxacin 1.9 0.0 [0.0 - 1.7] 98.1 0.5 1.4
Nalidixic acid N/A 0.0 [0.0 - 1.7] 29.7 67.0 0.5 2.9
Cephems Cefoxitin 0.5 5.3 [2.7 - 9.2] 5.3 83.3 4.3 1.4 0.5 1.0 4.3
Folate pathway inhibitors Sulfisoxazole N/A 4.8 [2.3 - 8.6] 3.8 38.8 52.2 0.5 4.8
Trimethoprim-sulfamethoxazole N/A 0.5 [0.0 - 2.6] 97.1 2.4 0.5
Phenicols Chloramphenicol 0.0 4.8 [2.3 - 8.6] 0.5 70.8 23.9 4.8
Tetracyclines Tetracycline 1.0 6.2 [3.4 - 10.4] 92.8 1.0 1.0 5.3
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 6.  Antimicrobial resistance pattern for Salmonella ser. Newport, 2013 
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Table 19.  Percentage and number of Salmonella ser. Newport isolates resistant to antimicrobial agents, 
2004–2013 
2004
192
2005
207
2006
219
2007
222
2008
258
2009
239
2010
306
2011
285
2012
258
2013
209
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.5%
1
1.0%
2
0.9%
2
0.9%
2
0.4%
1
0.4%
1
0.3%
1
0.7%
2
0.0%
0
0.5%
1
Kanamycin
(MIC ≥ 64)
2.6%
5
1.9%
4
2.7%
6
0.9%
2
3.5%
9
1.7%
4
0.7%
2
0.4%
1
0.0%
0
0.5%
1
Streptomycin
(MIC ≥ 64)
16.1%
31
14.0%
29
14.2%
31
10.4%
23
13.6%
35
8.4%
20
8.5%
26
4.2%
12
3.9%
10
5.7%
12
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
15.6%
30
12.6%
26
12.8%
28
8.1%
18
12.4%
32
7.5%
18
7.8%
24
3.9%
11
6.2%
16
5.3%
11
Ceftiofur
(MIC ≥ 8)
15.6%
30
12.6%
26
12.8%
28
8.1%
18
12.4%
32
7.1%
17
7.5%
23
3.9%
11
6.2%
16
5.3%
11
Ceftriaxone
(MIC ≥ 4)
15.1%
29
12.6%
26
13.2%
29
8.1%
18
12.4%
32
7.1%
17
7.5%
23
3.9%
11
6.2%
16
5.3%
11
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
16.1%
31
14.0%
29
15.5%
34
9.9%
22
14.3%
37
8.4%
20
7.8%
24
3.9%
11
7.0%
18
6.2%
13
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
0.5%
1
0.0%
0
0.9%
2
0.0%
0
0.4%
1
0.0%
0
0.3%
1
0.4%
1
0.0%
0
0.0%
0
Cephems Cefoxitin
(MIC ≥ 32)
15.6%
30
12.6%
26
13.2%
29
8.1%
18
12.4%
32
6.7%
16
7.5%
23
3.9%
11
6.2%
16
5.3%
11
Sulfisoxazole
(MIC ≥ 512)
17.2%
33
15.5%
32
15.5%
34
10.4%
23
13.2%
34
8.8%
21
7.8%
24
4.6%
13
3.9%
10
4.8%
10
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
2.1%
4
1.9%
4
3.7%
8
1.8%
4
3.1%
8
1.3%
3
1.3%
4
0.0%
0
0.4%
1
0.5%
1
Phenicols Chloramphenicol
(MIC ≥ 32)
15.6%
30
13.5%
28
12.8%
28
9.5%
21
12.0%
31
7.5%
18
7.5%
23
3.5%
10
3.9%
10
4.8%
10
Tetracyclines Tetracycline
(MIC ≥ 16)
17.2%
33
14.5%
30
14.6%
32
9.9%
22
14.0%
36
8.8%
21
8.5%
26
4.6%
13
4.3%
11
6.2%
13
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 20.  Resistance patterns of Salmonella ser. Newport isolates, 2004–2013 
2004
192
2005
207
2006
219
2007
222
2008
258
2009
239
2010
306
2011
285
2012
258
2013
209
81.8%
157
84.1%
174
82.2%
180
89.2%
198
85.3%
220
89.1%
213
90.5%
277
94.4%
269
93.0%
240
91.9%
192
18.2%
35
15.9%
33
17.8%
39
10.8%
24
14.7%
38
10.9%
26
9.5%
29
5.6%
16
7.0%
18
8.1%
17
17.7%
34
15.0%
31
16.9%
37
10.8%
24
13.6%
35
9.2%
22
8.2%
25
4.6%
13
6.6%
17
5.7%
12
16.7%
32
14.5%
30
15.5%
34
10.8%
24
13.6%
35
8.4%
20
7.8%
24
3.9%
11
6.2%
16
5.7%
12
16.1%
31
14.0%
29
13.7%
30
9.5%
21
13.6%
35
7.5%
18
7.8%
24
3.9%
11
3.9%
10
4.8%
10
15.1%
29
12.6%
26
13.2%
29
8.6%
19
12.8%
33
7.1%
17
7.5%
23
3.5%
10
3.9%
10
4.8%
10
15.1%
29
12.6%
26
12.3%
27
8.6%
19
11.6%
30
7.1%
17
7.5%
23
3.5%
10
3.9%
10
4.8%
10
0.0%
0
0.5%
1
1.4%
3
0.5%
1
1.6%
4
0.0%
0
0.3%
1
0.0%
0
0.0%
0
0.0%
0
1.0%
2
1.9%
4
2.7%
6
0.5%
1
2.7%
7
1.3%
3
1.3%
4
0.0%
0
0.4%
1
0.5%
1
15.1%
29
12.6%
26
11.0%
24
8.1%
18
11.6%
30
7.1%
17
7.5%
23
3.5%
10
3.9%
10
4.8%
10
15.1%
29
12.6%
26
12.3%
27
8.1%
18
12.4%
32
7.1%
17
7.5%
23
3.9%
11
6.2%
16
5.3%
11
0.5%
1
0.0%
0
0.5%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.4%
1
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
At least AAuCx**
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
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D. Salmonella ser. I 4,[5],12:i:-  
 
Table 21.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. I 4,[5],12:i:- 
isolates to antimicrobial agents, 2013 (N=127) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.8 4.7 [1.7 - 10.0] 3.9 78.0 11.8 0.8 0.8 1.6 3.1
Kanamycin 0.0 0.8 [0.0 - 4.3] 98.4 0.8 0.8
Streptomycin N/A 53.5 [44.5 - 62.4] 46.5 2.4 51.2
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.8 1.6 [0.2 - 5.6] 45.7 4.7 3.9 43.3 0.8 1.6
Cephems Ceftiofur 0.0 1.6 [0.2 - 5.6] 8.7 84.3 5.5 1.6
Ceftriaxone 0.0 1.6 [0.2 - 5.6] 97.6 0.8 0.8 0.8
Macrolide Azithromycin N/A 1.6 [0.2 - 5.6] 4.7 88.2 2.4 3.1 1.6
Penicillins Ampicillin 0.0 49.6 [40.6 - 58.6] 45.7 2.4 2.4 49.6
Quinolones Ciprofloxacin 1.6 0.8 [0.0 - 4.3] 81.1 15.0 1.6 0.8 0.8 0.8
Nalidixic acid N/A 0.8 [0.0 - 4.3] 18.1 76.4 2.4 2.4 0.8
Cephems Cefoxitin 0.8 1.6 [0.2 - 5.6] 5.5 75.6 14.2 2.4 0.8 1.6
Folate pathway inhibitors Sulfisoxazole N/A 53.5 [44.5 - 62.4] 2.4 30.7 12.6 0.8 53.5
Trimethoprim-sulfamethoxazole N/A 2.4 [0.5 - 6.7] 95.3 2.4 2.4
Phenicols Chloramphenicol 3.1 2.4 [0.5 - 6.7] 0.8 29.9 63.8 3.1 2.4
Tetracyclines Tetracycline 0.0 55.1 [46.0 - 64.0] 44.9 55.1
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 7.  Antimicrobial resistance pattern for Salmonella ser. I 4,[5],12:i:-, 2013 
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Table 22.  Percentage and number of Salmonella ser. I 4,[5],12:i:- isolates resistant to antimicrobial 
agents, 2004–2013 
2004
36
2005
33
2006
105
2007
73
2008
84
2009
72
2010
78
2011
82
2012
117
2013
127
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
5.6%
2
0.0%
0
4.8%
5
1.4%
1
3.6%
3
2.8%
2
1.3%
1
2.4%
2
2.6%
3
4.7%
6
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
1.4%
1
1.2%
1
0.0%
0
1.3%
1
0.0%
0
0.0%
0
0.8%
1
Streptomycin
(MIC ≥ 64)
5.6%
2
3.0%
1
3.8%
4
8.2%
6
10.7%
9
12.5%
9
19.2%
15
24.4%
20
29.1%
34
53.5%
68
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
2.8%
1
3.0%
1
3.8%
4
1.4%
1
4.8%
4
4.2%
3
3.8%
3
3.7%
3
1.7%
2
1.6%
2
Ceftiofur
(MIC ≥ 8)
2.8%
1
3.0%
1
3.8%
4
2.7%
2
4.8%
4
2.8%
2
2.6%
2
3.7%
3
0.9%
1
1.6%
2
Ceftriaxone
(MIC ≥ 4)
2.8%
1
3.0%
1
3.8%
4
2.7%
2
4.8%
4
2.8%
2
2.6%
2
3.7%
3
0.9%
1
1.6%
2
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
1.6%
2
Penicillins Ampicillin
(MIC ≥ 32)
5.6%
2
6.1%
2
6.7%
7
5.5%
4
9.5%
8
11.1%
8
21.8%
17
25.6%
21
29.1%
34
49.6%
63
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.3%
1
0.0%
0
0.0%
0
0.8%
1
Nalidixic Acid
(MIC ≥ 32)
2.8%
1
0.0%
0
1.0%
1
1.4%
1
1.2%
1
0.0%
0
2.6%
2
0.0%
0
0.0%
0
0.8%
1
Cephems Cefoxitin
(MIC ≥ 32)
2.8%
1
3.0%
1
3.8%
4
1.4%
1
4.8%
4
2.8%
2
2.6%
2
4.9%
4
0.9%
1
1.6%
2
Sulfisoxazole
(MIC ≥ 512)
11.1%
4
0.0%
0
8.6%
9
4.1%
3
13.1%
11
13.9%
10
19.2%
15
23.2%
19
29.1%
34
53.5%
68
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
2.8%
1
0.0%
0
0.0%
0
1.4%
1
4.8%
4
1.4%
1
1.3%
1
1.2%
1
0.0%
0
2.4%
3
Phenicols Chloramphenicol
(MIC ≥ 32)
2.8%
1
0.0%
0
1.9%
2
1.4%
1
6.0%
5
8.3%
6
1.3%
1
1.2%
1
0.0%
0
2.4%
3
Tetracyclines Tetracycline
(MIC ≥ 16)
11.1%
4
3.0%
1
8.6%
9
9.6%
7
16.7%
14
16.7%
12
28.2%
22
25.6%
21
33.3%
39
55.1%
70
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 23.  Resistance patterns of Salmonella ser. I 4,[5],12:i:- isolates, 2004–2013 
2004
36
2005
33
2006
105
2007
73
2008
84
2009
72
2010
78
2011
82
2012
117
2013
127
80.6%
29
87.9%
29
85.7%
90
82.2%
60
76.2%
64
76.4%
55
66.7%
52
65.9%
54
62.4%
73
39.4%
50
19.4%
7
12.1%
4
14.3%
15
17.8%
13
23.8%
20
23.6%
17
33.3%
26
34.1%
28
37.6%
44
60.6%
77
13.9%
5
3.0%
1
11.4%
12
6.8%
5
17.9%
15
16.7%
12
21.8%
17
28.0%
23
31.6%
37
54.3%
69
8.3%
3
3.0%
1
9.5%
10
5.5%
4
10.7%
9
12.5%
9
21.8%
17
26.8%
22
28.2%
33
51.2%
65
2.8%
1
0.0%
0
3.8%
4
2.7%
2
7.1%
6
9.7%
7
19.2%
15
19.5%
16
26.5%
31
48.8%
62
2.8%
1
0.0%
0
2.9%
3
1.4%
1
4.8%
4
6.9%
5
3.8%
3
0.0%
0
0.9%
1
2.4%
3
2.8%
1
0.0%
0
1.9%
2
1.4%
1
3.6%
3
6.9%
5
1.3%
1
0.0%
0
0.0%
0
0.8%
1
0.0%
0
0.0%
0
1.0%
1
0.0%
0
1.2%
1
1.4%
1
16.7%
13
18.3%
15
26.5%
31
46.5%
59
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.8%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
2.4%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
2.8%
1
3.0%
1
3.8%
4
1.4%
1
4.8%
4
2.8%
2
2.6%
2
3.7%
3
0.9%
1
1.6%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.8%
1
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
At least AAuCx**
  
 E. Salmonella ser. Infantis 
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Table 24.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Infantis isolates to 
antimicrobial agents, 2013 (N=76) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 3.9 [0.8 - 11.1] 17.1 69.7 6.6 2.6 2.6 1.3
Kanamycin 0.0 3.9 [0.8 - 11.1] 96.1 3.9
Streptomycin N/A 3.9 [0.8 - 11.1] 96.1 3.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 1.3 3.9 [0.8 - 11.1] 88.2 5.3 1.3 1.3 1.3 2.6
Cephems Ceftiofur 0.0 6.6 [2.2 - 14.7] 2.6 86.8 3.9 6.6
Ceftriaxone 0.0 6.6 [2.2 - 14.7] 93.4 1.3 2.6 2.6
Macrolide Azithromycin N/A 0.0 [0.0 - 4.7] 78.9 21.1
Penicillins Ampicillin 0.0 9.2 [3.8 - 18.1] 90.8 9.2
Quinolones Ciprofloxacin 3.9 0.0 [0.0 - 4.7] 85.5 9.2 1.3 2.6 1.3
Nalidixic acid N/A 5.3 [1.4 - 12.9] 55.3 39.5 1.3 3.9
Cephems Cefoxitin 0.0 3.9 [0.8 - 11.1] 9.2 86.8 3.9
Folate pathway inhibitors Sulfisoxazole N/A 9.2 [3.8 - 18.1] 9.2 50.0 31.6 9.2
Trimethoprim-sulfamethoxazole N/A 3.9 [0.8 - 11.1] 94.7 1.3 3.9
Phenicols Chloramphenicol 0.0 3.9 [0.8 - 11.1] 14.5 81.6 3.9
Tetracyclines Tetracycline 0.0 13.2 [6.5 - 22.9] 86.8 13.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 8.  Antimicrobial resistance pattern for Salmonella ser. Infantis, 2013 
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Table 25.  Percentage and number of Salmonella ser. Infantis isolates resistant to antimicrobial agents, 
2004–2013 
2004
29
2005
30
2006
22
2007
26
2008
51
2009
44
2010
53
2011
63
2012
90
2013
76
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
4.5%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.6%
1
0.0%
0
3.9%
3
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
6.8%
3
0.0%
0
0.0%
0
2.2%
2
3.9%
3
Streptomycin
(MIC ≥ 64)
0.0%
0
3.3%
1
4.5%
1
3.8%
1
2.0%
1
6.8%
3
1.9%
1
4.8%
3
0.0%
0
3.9%
3
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
9.1%
4
3.8%
2
1.6%
1
1.1%
1
3.9%
3
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.0%
0
3.8%
1
0.0%
0
11.4%
5
3.8%
2
1.6%
1
2.2%
2
6.6%
5
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
3.8%
1
0.0%
0
11.4%
5
3.8%
2
1.6%
1
2.2%
2
6.6%
5
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
3.8%
1
2.0%
1
13.6%
6
5.7%
3
1.6%
1
2.2%
2
9.2%
7
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
3.4%
1
3.3%
1
0.0%
0
0.0%
0
2.0%
1
2.3%
1
0.0%
0
1.6%
1
4.4%
4
5.3%
4
Cephems Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
11.4%
5
3.8%
2
1.6%
1
1.1%
1
3.9%
3
Sulfisoxazole
(MIC ≥ 512)
3.4%
1
6.7%
2
9.1%
2
3.8%
1
3.9%
2
6.8%
3
7.5%
4
4.8%
3
3.3%
3
9.2%
7
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
3.4%
1
0.0%
0
0.0%
0
0.0%
0
2.0%
1
2.3%
1
1.9%
1
1.6%
1
4.4%
4
3.9%
3
Phenicols Chloramphenicol
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
2.0%
1
4.5%
2
3.8%
2
1.6%
1
1.1%
1
3.9%
3
Tetracyclines Tetracycline
(MIC ≥ 16)
0.0%
0
3.3%
1
4.5%
1
7.7%
2
3.9%
2
11.4%
5
3.8%
2
4.8%
3
4.4%
4
13.2%
10
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 26.  Resistance patterns of Salmonella ser. Infantis isolates, 2004–2013 
2004
29
2005
30
2006
22
2007
26
2008
51
2009
44
2010
53
2011
63
2012
90
2013
76
93.1%
27
90.0%
27
90.9%
20
92.3%
24
96.1%
49
84.1%
37
88.7%
47
93.7%
59
92.2%
83
81.6%
62
6.9%
2
10.0%
3
9.1%
2
7.7%
2
3.9%
2
15.9%
7
11.3%
6
6.3%
4
7.8%
7
18.4%
14
0.0%
0
3.3%
1
9.1%
2
7.7%
2
3.9%
2
15.9%
7
7.5%
4
6.3%
4
4.4%
4
11.8%
9
0.0%
0
3.3%
1
4.5%
1
7.7%
2
3.9%
2
15.9%
7
3.8%
2
6.3%
4
4.4%
4
10.5%
8
0.0%
0
0.0%
0
0.0%
0
0.0%
0
2.0%
1
9.1%
4
1.9%
1
3.2%
2
2.2%
2
5.3%
4
0.0%
0
0.0%
0
0.0%
0
0.0%
0
2.0%
1
4.5%
2
1.9%
1
0.0%
0
2.2%
2
5.3%
4
0.0%
0
0.0%
0
0.0%
0
0.0%
0
2.0%
1
4.5%
2
1.9%
1
0.0%
0
0.0%
0
1.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
4.5%
2
1.9%
1
0.0%
0
0.0%
0
1.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
9.1%
4
3.8%
2
1.6%
1
1.1%
1
3.9%
3
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.1%
1
2.6%
2
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ASSuT‡ and not resistant to 
chloramphenicol
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
At least ACT/S§
At least ACSSuTAuCx¶
At least AAuCx**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
  
 F. Salmonella ser. Heidelberg 
50 
 
Table 27.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Heidelberg 
isolates to antimicrobial agents, 2013 (N=60) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 21.7 [12.1 - 34.2] 1.7 66.7 10.0 5.0 16.7
Kanamycin 3.3 26.7 [16.1 - 39.7] 70.0 3.3 5.0 21.7
Streptomycin N/A 40.0 [27.6 - 53.5] 60.0 11.7 28.3
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 8.3 13.3 [5.9 - 24.6] 65.0 1.7 11.7 8.3 13.3
Cephems Ceftiofur 0.0 15.0 [7.1 - 26.6] 5.0 78.3 1.7 15.0
Ceftriaxone 0.0 15.0 [7.1 - 26.6] 85.0 1.7 8.3 5.0
Macrolide Azithromycin N/A 0.0 [0.0 - 6.0] 83.3 16.7
Penicillins Ampicillin 0.0 33.3 [21.7 - 46.7] 65.0 1.7 33.3
Quinolones Ciprofloxacin 0.0 0.0 [0.0 - 6.0] 96.7 3.3
Nalidixic acid N/A 0.0 [0.0 - 6.0] 20.0 80.0
Cephems Cefoxitin 0.0 15.0 [7.1 - 26.6] 18.3 58.3 8.3 5.0 10.0
Folate pathway inhibitors Sulfisoxazole N/A 15.0 [7.1 - 26.6] 16.7 65.0 3.3 15.0
Trimethoprim-sulfamethoxazole N/A 1.7 [0.0 - 8.9] 96.7 1.7 1.7
Phenicols Chloramphenicol 1.7 6.7 [1.8 - 16.2] 23.3 68.3 1.7 6.7
Tetracyclines Tetracycline 0.0 33.3 [21.7 - 46.7] 66.7 1.7 31.7
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 9.  Antimicrobial resistance pattern for Salmonella ser. Heidelberg, 2013 
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Table 28.  Percentage and number of Salmonella ser. Heidelberg isolates resistant to antimicrobial 
agents, 2004–2013 
2004
92
2005
125
2006
102
2007
98
2008
75
2009
86
2010
62
2011
70
2012
41
2013
60
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
4.3%
4
6.4%
8
4.9%
5
16.3%
16
14.7%
11
2.3%
2
8.1%
5
20.0%
14
7.3%
3
21.7%
13
Kanamycin
(MIC ≥ 64)
8.7%
8
12.8%
16
8.8%
9
11.2%
11
26.7%
20
20.9%
18
21.0%
13
21.4%
15
9.8%
4
26.7%
16
Streptomycin
(MIC ≥ 64)
15.2%
14
13.6%
17
11.8%
12
12.2%
12
30.7%
23
23.3%
20
25.8%
16
37.1%
26
17.1%
7
40.0%
24
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
9.8%
9
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
10.0%
7
22.0%
9
13.3%
8
Ceftiofur
(MIC ≥ 8)
8.7%
8
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
8.6%
6
22.0%
9
15.0%
9
Ceftriaxone
(MIC ≥ 4)
8.7%
8
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
8.6%
6
22.0%
9
15.0%
9
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
25.0%
23
20.0%
25
18.6%
19
18.4%
18
28.0%
21
27.9%
24
38.7%
24
30.0%
21
26.8%
11
33.3%
20
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Nalidixic Acid
(MIC ≥ 32)
0.0%
0
0.8%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Cephems Cefoxitin
(MIC ≥ 32)
7.6%
7
8.8%
11
8.8%
9
7.1%
7
8.0%
6
19.8%
17
24.2%
15
8.6%
6
22.0%
9
15.0%
9
Sulfisoxazole
(MIC ≥ 512)
7.6%
7
8.0%
10
4.9%
5
18.4%
18
12.0%
9
7.0%
6
11.3%
7
7.1%
5
2.4%
1
15.0%
9
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.0%
0
0.8%
1
0.0%
0
0.0%
0
2.7%
2
3.5%
3
0.0%
0
1.4%
1
0.0%
0
1.7%
1
Phenicols Chloramphenicol
(MIC ≥ 32)
1.1%
1
0.8%
1
0.0%
0
3.1%
3
1.3%
1
4.7%
4
1.6%
1
4.3%
3
0.0%
0
6.7%
4
Tetracyclines Tetracycline
(MIC ≥ 16)
19.6%
18
18.4%
23
13.7%
14
22.4%
22
36.0%
27
27.9%
24
22.6%
14
34.3%
24
14.6%
6
33.3%
20
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 29.  Resistance patterns of Salmonella ser. Heidelberg isolates, 2004–2013 
2004
92
2005
125
2006
102
2007
98
2008
75
2009
86
2010
62
2011
70
2012
41
2013
60
56.5%
52
62.4%
78
67.6%
69
58.2%
57
57.3%
43
60.5%
52
53.2%
33
55.7%
39
61.0%
25
46.7%
28
43.5%
40
37.6%
47
32.4%
33
41.8%
41
42.7%
32
39.5%
34
46.8%
29
44.3%
31
39.0%
16
53.3%
32
22.8%
21
24.8%
31
23.5%
24
28.6%
28
40.0%
30
34.9%
30
41.9%
26
44.3%
31
39.0%
16
51.7%
31
13.0%
12
15.2%
19
12.7%
13
17.3%
17
28.0%
21
25.6%
22
33.9%
21
30.0%
21
26.8%
11
33.3%
20
4.3%
4
4.8%
6
2.0%
2
5.1%
5
13.3%
10
17.4%
15
11.3%
7
4.3%
3
2.4%
1
8.3%
5
3.3%
3
1.6%
2
2.0%
2
4.1%
4
6.7%
5
15.1%
13
9.7%
6
4.3%
3
0.0%
0
6.7%
4
1.1%
1
0.0%
0
0.0%
0
3.1%
3
1.3%
1
3.5%
3
1.6%
1
1.4%
1
0.0%
0
6.7%
4
3.3%
3
0.8%
1
0.0%
0
0.0%
0
6.7%
5
2.3%
2
6.5%
4
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
3.5%
3
0.0%
0
1.4%
1
0.0%
0
1.7%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.2%
1
0.0%
0
1.4%
1
0.0%
0
1.7%
1
8.7%
8
8.8%
11
9.8%
10
7.1%
7
8.0%
6
20.9%
18
24.2%
15
8.6%
6
22.0%
9
13.3%
8
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
Year
Total Isolates
Resistance Pattern
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
At least AAuCx**
At least ceftriaxone and nalidixic acid 
resistant
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
  
 52 
2. Typhoidal Salmonella 
 
A. Salmonella ser. Typhi 
 
Table 30.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhi isolates to 
antimicrobial agents, 2013 (N=279)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.3] 87.8 12.2
Kanamycin 0.0 0.0 [0.0 - 1.3] 100.0
Streptomycin N/A 7.9 [5.0 - 11.7] 92.1 7.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.7 0.0 [0.0 - 1.3] 89.2 2.2 7.9 0.7
Cephems Ceftiofur 0.0 0.0 [0.0 - 1.3] 0.4 5.0 74.6 20.1
Ceftriaxone 0.0 0.0 [0.0 - 1.3] 99.6 0.4
Macrolide Azithromycin N/A 0.0 [0.0 - 1.3] 1.8 26.9 68.5 2.5 0.4
Penicillins Ampicillin 0.0 10.4 [7.1 - 14.6] 89.2 0.4 10.4
Quinolones Ciprofloxacin 60.9 8.6 [5.6 - 12.5] 29.7 0.7 9.7 35.5 15.8 0.4 0.4 0.4 7.5
Nalidixic acid N/A 67.4 [61.5 - 72.9] 0.4 2.9 25.8 0.7 2.2 0.7 67.4
Cephems Cefoxitin 0.7 0.0 [0.0 - 1.3] 3.2 29.4 14.0 45.5 7.2 0.7
Folate pathway inhibitors Sulfisoxazole N/A 11.1 [7.7 - 15.4] 60.6 23.7 3.9 0.4 0.4 11.1
Trimethoprim-sulfamethoxazole N/A 10.8 [7.4 - 15.0] 88.9 0.4 10.8
Phenicols Chloramphenicol 0.0 9.3 [6.2 - 13.4] 2.9 75.6 12.2 9.3
Tetracyclines Tetracycline 0.4 2.2 [0.8 - 4.6] 97.5 0.4 2.2
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 10.  Antimicrobial resistance pattern for Salmonella ser. Typhi, 2013 
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Table 31.  Percentage and number of Salmonella ser. Typhi isolates resistant to antimicrobial agents, 
2004–2013
2004
304
2005
318
2006
323
2007
400
2008
407
2009
363
2010
446
2011
383
2012
327
2013
279
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.0%
0
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
11.8%
36
13.2%
42
18.9%
61
15.8%
63
11.5%
47
10.7%
39
10.1%
45
10.7%
41
9.2%
30
7.9%
22
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.0%
0
0.3%
1
0.3%
1
0.0%
0
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
11.8%
36
13.2%
42
20.4%
66
17.0%
68
13.0%
53
12.7%
46
12.3%
55
11.2%
43
10.1%
33
10.4%
29
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.3%
1
0.9%
3
2.0%
8
0.7%
3
3.9%
14
4.3%
19
7.3%
28
6.7%
22
8.6%
24
Nalidixic Acid
(MIC ≥ 32)
41.8%
127
48.4%
154
54.5%
176
62.0%
248
59.0%
240
59.8%
217
69.3%
309
70.8%
271
68.5%
224
67.4%
188
Cephems Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.3%
1
0.5%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Sulfisoxazole
(MIC ≥ 512)
11.8%
36
14.2%
45
20.7%
67
17.5%
70
13.0%
53
13.8%
50
12.3%
55
12.0%
46
10.4%
34
11.1%
31
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
13.2%
40
14.5%
46
20.7%
67
16.3%
65
12.5%
51
12.7%
46
11.9%
53
11.7%
45
10.1%
33
10.8%
30
Phenicols Chloramphenicol
(MIC ≥ 32)
13.2%
40
13.2%
42
19.5%
63
15.8%
63
12.8%
52
11.8%
43
11.7%
52
10.7%
41
10.1%
33
9.3%
26
Tetracyclines Tetracycline
(MIC ≥ 16)
8.9%
27
10.1%
32
8.4%
27
6.3%
25
4.4%
18
6.1%
22
3.6%
16
4.4%
17
1.5%
5
2.2%
6
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 32.  Resistance patterns of Salmonella ser. Typhi isolates, 2004–2013 
2004
304
2005
318
2006
323
2007
400
2008
407
2009
363
2010
446
2011
383
2012
327
2013
279
56.6%
172
48.1%
153
40.2%
130
35.5%
142
38.3%
156
37.5%
136
29.4%
131
27.9%
107
30.6%
100
29.4%
82
43.4%
132
51.9%
165
59.8%
193
64.5%
258
61.7%
251
62.5%
227
70.6%
315
72.1%
276
69.4%
227
70.6%
197
13.2%
40
14.5%
46
21.7%
70
18.0%
72
14.3%
58
14.6%
53
13.7%
61
12.5%
48
11.0%
36
11.5%
32
12.8%
39
13.8%
44
20.7%
67
17.5%
70
13.3%
54
13.2%
48
13.7%
61
12.3%
47
10.4%
34
10.4%
29
12.5%
38
12.9%
41
19.2%
62
17.0%
68
12.8%
52
12.7%
46
11.7%
52
11.2%
43
9.5%
31
9.0%
25
11.8%
36
11.9%
38
16.7%
54
14.8%
59
10.8%
44
10.2%
37
9.6%
43
9.9%
38
8.9%
29
7.2%
20
7.9%
24
9.1%
29
5.9%
19
3.8%
15
2.5%
10
2.8%
10
1.6%
7
2.3%
9
0.9%
3
0.4%
1
0.0%
0
0.0%
0
0.6%
2
0.2%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.4%
1
11.8%
36
12.9%
41
18.6%
60
15.2%
61
12.0%
49
11.0%
40
10.5%
47
10.4%
40
9.2%
30
8.2%
23
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
At least AAuCx**
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
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B. Salmonella  ser. Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C 
 
Table 33.  Frequency* of Salmonella ser. Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C, 
2013  
n (%)
Paratyphi A 100 (99.0)
Paratyphi B 1 (1.0)
Paratyphi C 0 (0)
Total 101 (100)
Serotype* 2013
 
*See Methods for varying sampling method by serotype 
 
Table 34.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Paratyphi A 
isolates to antimicrobial agents, 2013 (N=100) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 3.6] 93.0 6.0 1.0
Kanamycin 0.0 0.0 [0.0 - 3.6] 99.0 1.0
Streptomycin N/A 1.0 [0.0 - 5.4] 99.0 1.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.0 [0.0 - 3.6] 30.0 67.0 3.0
Cephems Ceftiofur 0.0 0.0 [0.0 - 3.6] 1.0 2.0 91.0 6.0
Ceftriaxone 0.0 0.0 [0.0 - 3.6] 100.0
Macrolide Azithromycin N/A 0.0 [0.0 - 3.6] 2.0 19.0 72.0 7.0
Penicillins Ampicillin 0.0 0.0 [0.0 - 3.6] 5.0 88.0 7.0
Quinolones Ciprofloxacin 78.0 4.0 [1.1 - 9.9] 9.0 9.0 3.0 1.0 74.0 4.0
Nalidixic acid N/A 81.0 [71.9 - 88.2] 2.0 17.0 81.0
Cephems Cefoxitin 1.0 0.0 [0.0 - 3.6] 6.0 69.0 24.0 1.0
Folate pathway inhibitors Sulfisoxazole N/A 0.0 [0.0 - 3.6] 13.0 84.0 3.0
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0 - 3.6] 97.0 3.0
Phenicols Chloramphenicol 6.0 0.0 [0.0 - 3.6] 6.0 88.0 6.0
Tetracyclines Tetracycline 0.0 0.0 [0.0 - 3.6] 100.0
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
Figure 11.  Antimicrobial resistance pattern for Salmonella ser. Paratyphi A, 2013 
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Table 35.  Percentage and number of Salmonella ser. Paratyphi A isolates resistant to antimicrobial 
agents, 2004–2013 
2004
8
2005
12
2006
10
2007
16
2008
116
2009
99
2010
145
2011
152
2012
111
2013
100
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
0.0%
0
0.0%
0
0.0%
0
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
0.0%
0
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
2.1%
3
0.0%
0
0.0%
0
1.0%
1
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
0.0%
0
0.0%
0
Ciprofloxacin
(MIC ≥ 1)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.9%
1
0.0%
0
2.8%
4
2.0%
3
2.7%
3
4.0%
4
Nalidixic Acid
(MIC ≥ 32)
100.0%
8
91.7%
11
80.0%
8
93.8%
15
88.8%
103
86.9%
86
92.4%
134
96.7%
147
94.6%
105
81.0%
81
Cephems Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Sulfisoxazole
(MIC ≥ 512)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
0.0%
0
0.0%
0
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
2.1%
3
0.0%
0
0.0%
0
0.0%
0
Phenicols Chloramphenicol
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
0.9%
1
0.0%
0
Tetracyclines Tetracycline
(MIC ≥ 16)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.9%
1
1.0%
1
1.4%
2
0.0%
0
0.9%
1
0.0%
0
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
Table 36.  Resistance patterns of Salmonella ser. Paratyphi A isolates, 2004–2013  
2004
8
2005
12
2006
10
2007
16
2008
116
2009
99
2010
145
2011
152
2012
111
2013
100
0.0%
0
8.3%
1
20.0%
2
6.3%
1
10.3%
12
12.1%
12
5.5%
8
3.3%
5
5.4%
6
19.0%
19
100.0%
8
91.7%
11
80.0%
8
93.8%
15
89.7%
104
87.9%
87
94.5%
137
96.7%
147
94.6%
105
81.0%
81
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
2.8%
4
0.0%
0
0.9%
1
1.0%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
0.9%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
1.4%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
0.7%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
0.7%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.0%
1
0.7%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
At least ASSuT‡ and not resistant to 
chloramphenicol
At least ACT/S§
At least ACSSuTAuCx¶
At least AAuCx**
At least ceftriaxone and nalidixic acid 
resistant
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
Resistance ≥ 1 CLSI* class
Year
Total Isolates
Resistance Pattern
No resistance detected 
  
 3. Shigella 
56 
 
Table 37.  Frequency of Shigella species, 2013 
n (%)
Shigella sonnei 275 (79.9)
Shigella flexneri 64 (18.6)
Shigella dysenteriae 4 (1.2)
Shigella  boydii 1 (0.3)
Total 344 (100)
Species 2013
 
 
Table 38.  Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial 
agents, 2013 (N=344)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.3 [0.0 - 1.6] 0.6 8.4 85.5 4.7 0.6 0.3
Kanamycin 0.0 0.0 [0.0 - 1.1] 100.0
Streptomycin N/A 91.6 [88.1 - 94.3] 8.4 36.6 54.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 15.1 2.9 [1.4 - 5.3] 1.7 3.5 53.8 23.0 15.1 1.2 1.7
Cephems Ceftiofur 0.0 1.2 [0.3 - 3.0] 6.4 64.0 21.8 6.7 1.2
Ceftriaxone 0.0 1.2 [0.3 - 3.0] 96.5 2.3 0.3 0.3 0.6
Macrolide Azithromycin N/A 3.8 [2.0 - 6.4] 0.6 2.6 4.1 9.3 62.5 16.6 0.6 3.8
Penicillins Ampicillin 0.3 36.0 [31.0 - 41.4] 5.2 42.2 15.7 0.6 0.3 1.2 34.9
Quinolones Ciprofloxacin 0.0 3.5 [1.8 - 6.0] 93.9 0.3 1.2 1.2 2.0 1.5
Nalidixic acid N/A 5.2 [3.1 - 8.1] 2.6 71.2 17.7 2.9 0.3 0.3 4.9
Cephems Cefoxitin 1.2 1.7 [0.6 - 3.8] 0.6 1.5 63.4 29.7 2.0 1.2 1.7
Folate pathway inhibitors Sulfisoxazole N/A 48.0 [42.6 - 53.4] 48.5 2.9 0.3 0.3 48.0
Trimethoprim-sulfamethoxazole N/A 49.7 [44.3 - 55.1] 6.4 2.3 11.3 17.7 12.5 1.7 48.0
Phenicols Chloramphenicol 0.6 11.6 [8.4 - 15.5] 9.0 71.5 7.3 0.6 3.8 7.8
Tetracyclines Tetracycline 0.6 43.6 [38.3 - 49.0] 55.8 0.6 5.5 38.1
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
Figure 12.  Antimicrobial resistance pattern for Shigella, 2013 
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Table 39.  Percentage and number of Shigella isolates resistant to antimicrobial agents, 2004–2013
2004
316
2005
396
2006
402
2007
480
2008
551
2009
475
2010
411
2011
293
2012
353
2013
344
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
1.0%
4
0.2%
1
0.8%
4
0.4%
2
0.6%
3
0.5%
2
0.7%
2
0.0%
0
0.3%
1
Kanamycin
(MIC ≥ 64)
0.0%
0
0.8%
3
0.0%
0
0.2%
1
0.5%
3
0.4%
2
0.0%
0
0.0%
0
0.3%
1
0.0%
0
Streptomycin
(MIC ≥ 64)
59.8%
189
68.7%
272
60.7%
244
73.3%
352
80.6%
444
89.1%
423
91.0%
374
87.7%
257
83.0%
293
91.6%
315
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
1.6%
5
1.0%
4
1.5%
6
0.4%
2
3.3%
18
2.1%
10
0.0%
0
2.0%
6
1.7%
6
2.9%
10
Ceftiofur
(MIC ≥ 8)
0.3%
1
0.5%
2
0.2%
1
0.0%
0
0.0%
0
0.6%
3
0.2%
1
1.7%
5
1.1%
4
1.2%
4
Ceftriaxone
(MIC ≥ 4)
0.3%
1
0.5%
2
0.2%
1
0.0%
0
0.0%
0
0.6%
3
0.2%
1
1.7%
5
1.1%
4
1.2%
4
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
3.4%
10
4.0%
14
3.8%
13
Penicillins Ampicillin
(MIC ≥ 32)
77.5%
245
70.7%
280
62.4%
251
63.8%
306
62.4%
344
46.3%
220
40.9%
168
33.8%
99
25.5%
90
36.0%
124
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.2%
1
0.2%
1
0.7%
4
0.6%
3
1.7%
7
2.4%
7
2.0%
7
3.5%
12
Nalidixic Acid
(MIC ≥ 32)
1.6%
5
1.5%
6
3.5%
14
1.7%
8
1.6%
9
2.1%
10
4.4%
18
6.1%
18
4.5%
16
5.2%
18
Cephems Cefoxitin
(MIC ≥ 32)
0.3%
1
0.5%
2
0.0%
0
0.0%
0
0.0%
0
0.6%
3
0.0%
0
1.0%
3
0.6%
2
1.7%
6
Sulfisoxazole
(MIC ≥ 512)
52.5%
166
57.6%
228
40.3%
162
25.8%
124
28.5%
157
30.5%
145
29.9%
123
44.7%
131
34.8%
123
48.0%
165
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
46.8%
148
53.3%
211
46.0%
185
25.8%
124
31.2%
172
40.4%
192
47.7%
196
66.9%
196
43.3%
153
49.7%
171
Phenicols Chloramphenicol
(MIC ≥ 32)
15.2%
48
10.9%
43
10.9%
44
8.3%
40
6.9%
38
9.3%
44
10.0%
41
12.3%
36
11.3%
40
11.6%
40
Tetracyclines Tetracycline
(MIC ≥ 16)
49.4%
156
38.4%
152
34.6%
139
25.6%
123
24.3%
134
29.5%
140
31.4%
129
40.6%
119
37.1%
131
43.6%
150
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
 
Table 40.  Resistance patterns of Shigella isolates, 2004–2013
2004
316
2005
396
2006
402
2007
480
2008
551
2009
475
2010
411
2011
293
2012
353
2013
344
4.7%
15
4.5%
18
6.5%
26
7.1%
34
4.5%
25
4.0%
19
3.6%
15
4.4%
13
7.4%
26
4.1%
14
95.3%
301
95.5%
378
93.5%
376
92.9%
446
95.5%
526
96.0%
456
96.4%
396
95.6%
280
92.6%
327
95.9%
330
64.2%
203
72.0%
285
64.7%
260
65.4%
314
68.2%
376
68.0%
323
69.8%
287
74.4%
218
53.8%
190
61.0%
210
59.5%
188
58.6%
232
43.8%
176
27.7%
133
35.2%
194
36.4%
173
39.7%
163
51.2%
150
37.4%
132
53.5%
184
32.9%
104
19.4%
77
15.4%
62
11.7%
56
10.3%
57
13.3%
63
14.1%
58
22.2%
65
19.3%
68
23.8%
82
7.0%
22
4.8%
19
5.2%
21
4.6%
22
2.7%
15
6.5%
31
4.6%
19
9.9%
29
7.6%
27
9.9%
34
6.0%
19
4.0%
16
5.0%
20
3.8%
18
2.2%
12
5.9%
28
4.4%
18
6.1%
18
5.7%
20
7.3%
25
6.6%
21
6.3%
25
6.0%
24
4.0%
19
2.9%
16
6.7%
32
4.9%
20
7.8%
23
7.4%
26
8.1%
28
34.5%
109
35.6%
141
26.6%
107
12.9%
62
16.0%
88
17.5%
83
17.8%
73
25.9%
76
15.6%
55
25.6%
88
0.6%
2
0.5%
2
0.5%
2
0.8%
4
0.0%
0
0.2%
1
1.2%
5
2.4%
7
0.8%
3
1.2%
4
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
0.3%
1
0.2%
1
0.0%
0
0.0%
0
0.0%
0
0.2%
1
1.4%
4
0.8%
3
0.3%
1
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.3%
1
0.3%
1
0.3%
1
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
At least ACSSuT† 
At least ACT/S‡
At least AT/S§
At least ANT/S¶
At least ACSSuTAuCx**
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
Year
Total Isolates
Resistance Pattern
No resistance detected 
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Table 41.  Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents, 2013 (N=275)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.3] 4.7 89.1 5.5 0.7
Kanamycin 0.0 0.0 [0.0 - 1.3] 100.0
Streptomycin N/A 97.8 [95.3 - 99.2] 2.2 44.0 53.8
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 6.5 3.6 [1.8 - 6.6] 0.4 64.7 24.7 6.5 1.5 2.2
Cephems Ceftiofur 0.0 0.7 [0.1 - 2.6] 1.5 67.6 23.3 6.9 0.7
Ceftriaxone 0.0 0.7 [0.1 - 2.6] 96.4 2.9 0.4 0.4
Macrolide Azithromycin N/A 1.1 [0.2 - 3.2] 0.4 3.3 74.2 20.4 0.7 1.1
Penicillins Ampicillin 0.4 28.0 [22.8 - 33.7] 0.7 50.9 19.3 0.7 0.4 1.1 26.9
Quinolones Ciprofloxacin 0.0 2.9 [1.3 - 5.7] 96.0 0.4 0.4 0.4 1.8 1.1
Nalidixic acid N/A 3.3 [1.5 - 6.1] 2.9 76.0 14.9 2.9 3.3
Cephems Cefoxitin 1.5 2.2 [0.8 - 4.7] 0.4 0.7 73.5 21.8 1.5 2.2
Folate pathway inhibitors Sulfisoxazole N/A 45.1 [39.1 - 51.2] 51.3 2.9 0.4 0.4 45.1
Trimethoprim-sulfamethoxazole N/A 47.6 [41.6 - 53.7] 0.7 1.1 12.7 22.2 15.6 2.2 45.5
Phenicols Chloramphenicol 0.7 0.7 [0.1 - 2.6] 3.3 87.3 8.0 0.7 0.7
Tetracyclines Tetracycline 0.4 34.9 [29.3 - 40.9] 64.7 0.4 4.4 30.5
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
Figure 13.  Antimicrobial resistance pattern for Shigella sonnei, 2013
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Table 42.  Percentage and number of Shigella sonnei isolates resistant to antimicrobial agents, 2004–2013
2004
241
2005
340
2006
321
2007
414
2008
494
2009
410
2010
337
2011
225
2012
287
2013
275
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
1.2%
4
0.0%
0
1.0%
4
0.4%
2
0.7%
3
0.0%
0
0.9%
2
0.0%
0
0.0%
0
Kanamycin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.2%
1
0.6%
3
0.2%
1
0.0%
0
0.0%
0
0.3%
1
0.0%
0
Streptomycin
(MIC ≥ 64)
56.8%
137
70.3%
239
61.7%
198
76.8%
318
82.4%
407
91.5%
375
96.1%
324
95.6%
215
89.2%
256
97.8%
269
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
1.7%
4
1.2%
4
1.9%
6
0.5%
2
3.2%
16
2.0%
8
0.0%
0
2.7%
6
1.7%
5
3.6%
10
Ceftiofur
(MIC ≥ 8)
0.4%
1
0.6%
2
0.0%
0
0.0%
0
0.0%
0
0.5%
2
0.3%
1
1.8%
4
1.0%
3
0.7%
2
Ceftriaxone
(MIC ≥ 4)
0.4%
1
0.6%
2
0.0%
0
0.0%
0
0.0%
0
0.5%
2
0.3%
1
1.8%
4
1.0%
3
0.7%
2
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.9%
2
2.1%
6
1.1%
3
Penicillins Ampicillin
(MIC ≥ 32)
79.3%
191
70.6%
240
62.6%
201
64.0%
265
61.3%
303
43.2%
177
36.8%
124
27.6%
62
18.1%
52
28.0%
77
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.6%
3
0.0%
0
1.5%
5
1.3%
3
2.1%
6
2.9%
8
Nalidixic Acid
(MIC ≥ 32)
1.7%
4
1.2%
4
2.8%
9
1.2%
5
1.6%
8
1.7%
7
3.3%
11
3.6%
8
4.2%
12
3.3%
9
Cephems Cefoxitin
(MIC ≥ 32)
0.4%
1
0.6%
2
0.0%
0
0.0%
0
0.0%
0
0.7%
3
0.0%
0
1.3%
3
0.7%
2
2.2%
6
Sulfisoxazole
(MIC ≥ 512)
49.0%
118
57.9%
197
33.3%
107
20.0%
83
24.5%
121
23.9%
98
25.2%
85
39.6%
89
30.0%
86
45.1%
124
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
46.9%
113
55.0%
187
42.7%
137
22.0%
91
29.1%
144
36.1%
148
46.9%
158
68.9%
155
41.8%
120
47.6%
131
Phenicols Chloramphenicol
(MIC ≥ 32)
2.5%
6
2.4%
8
0.9%
3
1.2%
5
0.8%
4
1.2%
5
1.5%
5
2.7%
6
3.1%
9
0.7%
2
Tetracyclines Tetracycline
(MIC ≥ 16)
36.1%
87
29.4%
100
22.7%
73
16.2%
67
16.8%
83
20.7%
85
21.4%
72
29.8%
67
27.5%
79
34.9%
96
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
 
Table 43.  Resistance patterns of Shigella sonnei isolates, 2004–2013
2004
241
2005
340
2006
321
2007
414
2008
494
2009
410
2010
337
2011
225
2012
287
2013
275
5.4%
13
4.4%
15
6.2%
20
6.8%
28
4.7%
23
3.7%
15
1.5%
5
0.9%
2
5.9%
17
0.7%
2
94.6%
228
95.6%
325
93.8%
301
93.2%
386
95.3%
471
96.3%
395
98.5%
332
99.1%
223
94.1%
270
99.3%
273
56.4%
136
70.6%
240
59.8%
192
63.0%
261
65.4%
323
65.4%
268
68.0%
229
73.8%
166
49.1%
141
56.4%
155
51.0%
123
55.3%
188
35.8%
115
21.3%
88
29.4%
145
29.8%
122
32.6%
110
44.9%
101
31.0%
89
48.0%
132
25.7%
62
12.4%
42
8.1%
26
5.1%
21
5.3%
26
5.9%
24
6.5%
22
13.3%
30
11.5%
33
14.5%
40
0.8%
2
0.9%
3
0.0%
0
1.2%
5
0.4%
2
0.5%
2
0.6%
2
3.6%
8
2.8%
8
1.8%
5
0.0%
0
0.3%
1
0.0%
0
0.5%
2
0.2%
1
0.0%
0
0.6%
2
0.4%
1
1.0%
3
0.4%
1
1.7%
4
2.4%
8
0.9%
3
0.5%
2
0.8%
4
1.0%
4
0.9%
3
2.2%
5
2.8%
8
0.7%
2
35.3%
85
35.6%
121
22.7%
73
9.4%
39
14.2%
70
12.2%
50
14.2%
48
22.2%
50
10.8%
31
19.3%
53
0.8%
2
0.3%
1
0.0%
0
0.7%
3
0.0%
0
0.0%
0
0.0%
0
1.3%
3
1.0%
3
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.4%
1
0.3%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.3%
1
1.3%
3
0.7%
2
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.3%
1
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
At least ACSSuT† 
At least ACT/S‡
At least AT/S§
At least ANT/S¶
At least ACSSuTAuCx**
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
Year
Total Isolates
Resistance Pattern
No resistance detected 
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Table 44.  Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
agents, 2013 (N=64)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 1.6 [0.0 - 8.4] 3.1 21.9 71.9 1.6 1.6
Kanamycin 0.0 0.0 [0.0 - 5.6] 100.0
Streptomycin N/A 67.2 [54.3 - 78.4] 32.8 7.8 59.4
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 53.1 0.0 [0.0 - 5.6] 6.3 17.2 9.4 14.1 53.1
Cephems Ceftiofur 0.0 3.1 [0.4 - 10.8] 25.0 51.6 14.1 6.3 3.1
Ceftriaxone 0.0 3.1 [0.4 - 10.8] 96.9 1.6 1.6
Macrolide Azithromycin N/A 15.6 [7.7 - 26.9] 3.1 14.1 20.3 31.3 15.6 15.6
Penicillins Ampicillin 0.0 70.3 [57.6 - 81.1] 21.9 7.8 1.6 68.8
Quinolones Ciprofloxacin 0.0 6.3 [1.7 - 15.2] 85.9 3.1 4.7 3.1 3.1
Nalidixic acid N/A 12.5 [5.5 - 23.2] 1.6 51.6 31.3 1.6 1.6 12.5
Cephems Cefoxitin 0.0 0.0 [0.0 - 5.6] 1.6 1.6 21.9 64.1 10.9
Folate pathway inhibitors Sulfisoxazole N/A 59.4 [46.4 - 71.5] 37.5 3.1 59.4
Trimethoprim-sulfamethoxazole N/A 57.8 [44.8 - 70.1] 28.1 7.8 6.3 57.8
Phenicols Chloramphenicol 0.0 59.4 [46.4 - 71.5] 31.3 6.3 3.1 20.3 39.1
Tetracyclines Tetracycline 0.0 81.3 [69.5 - 89.9] 18.8 9.4 71.9
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
Figure 14.  Antimicrobial resistance pattern for Shigella flexneri, 2013 
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Table 45.  Percentage and number of Shigella flexneri isolates resistant to antimicrobial agents, 2004–
2013
2004
62
2005
52
2006
74
2007
61
2008
49
2009
57
2010
61
2011
58
2012
59
2013
64
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
0.0%
0
3.3%
2
0.0%
0
0.0%
0
1.6%
1
Kanamycin
(MIC ≥ 64)
0.0%
0
3.8%
2
0.0%
0
0.0%
0
0.0%
0
1.8%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
71.0%
44
57.7%
30
58.1%
43
52.5%
32
63.3%
31
73.7%
42
68.9%
42
58.6%
34
55.9%
33
67.2%
43
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
1.6%
1
0.0%
0
0.0%
0
0.0%
0
4.1%
2
3.5%
2
0.0%
0
0.0%
0
1.7%
1
0.0%
0
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
1.8%
1
0.0%
0
1.7%
1
1.7%
1
3.1%
2
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
1.8%
1
0.0%
0
1.7%
1
1.7%
1
3.1%
2
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
12.1%
7
13.6%
8
15.6%
10
Penicillins Ampicillin
(MIC ≥ 32)
80.6%
50
75.0%
39
63.5%
47
63.9%
39
75.5%
37
70.2%
40
67.2%
41
60.3%
35
61.0%
36
70.3%
45
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
1.4%
1
1.6%
1
2.0%
1
3.5%
2
3.3%
2
6.9%
4
1.7%
1
6.3%
4
Nalidixic Acid
(MIC ≥ 32)
1.6%
1
3.8%
2
5.4%
4
4.9%
3
2.0%
1
3.5%
2
11.5%
7
12.1%
7
5.1%
3
12.5%
8
Cephems Cefoxitin
(MIC ≥ 32)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Sulfisoxazole
(MIC ≥ 512)
66.1%
41
55.8%
29
68.9%
51
62.3%
38
63.3%
31
73.7%
42
55.7%
34
60.3%
35
55.9%
33
59.4%
38
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
46.8%
29
44.2%
23
59.5%
44
49.2%
30
49.0%
24
68.4%
39
55.7%
34
58.6%
34
50.8%
30
57.8%
37
Phenicols Chloramphenicol
(MIC ≥ 32)
61.3%
38
65.4%
34
54.1%
40
55.7%
34
65.3%
32
66.7%
38
55.7%
34
50.0%
29
52.5%
31
59.4%
38
Tetracyclines Tetracycline
(MIC ≥ 16)
95.2%
59
94.2%
49
83.8%
62
83.6%
51
87.8%
43
87.7%
50
86.9%
53
79.3%
46
84.7%
50
81.3%
52
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
 
Table 46.  Resistance patterns of Shigella flexneri isolates, 2004–2013
2004
62
2005
52
2006
74
2007
61
2008
49
2009
57
2010
61
2011
58
2012
59
2013
64
0.0%
0
5.8%
3
5.4%
4
9.8%
6
4.1%
2
5.3%
3
9.8%
6
17.2%
10
11.9%
7
15.6%
10
100.0%
62
94.2%
49
94.6%
70
90.2%
55
95.9%
47
94.7%
54
90.2%
55
82.8%
48
88.1%
52
84.4%
54
93.5%
58
80.8%
42
85.1%
63
80.3%
49
93.9%
46
86.0%
49
83.6%
51
77.6%
45
76.3%
45
81.3%
52
90.3%
56
78.8%
41
75.7%
56
68.9%
42
85.7%
42
82.5%
47
80.3%
49
72.4%
42
67.8%
40
76.6%
49
64.5%
40
65.4%
34
47.3%
35
55.7%
34
57.1%
28
63.2%
36
57.4%
35
56.9%
33
57.6%
34
62.5%
40
29.0%
18
30.8%
16
28.4%
21
27.9%
17
26.5%
13
49.1%
28
27.9%
17
32.8%
19
32.2%
19
45.3%
29
27.4%
17
28.8%
15
27.0%
20
26.2%
16
22.4%
11
47.4%
27
26.2%
16
27.6%
16
28.8%
17
37.5%
24
24.2%
15
32.7%
17
28.4%
21
26.2%
16
24.5%
12
47.4%
27
27.9%
17
29.3%
17
30.5%
18
40.6%
26
35.5%
22
38.5%
20
43.2%
32
36.1%
22
32.7%
16
52.6%
30
41.0%
25
41.4%
24
37.3%
22
51.6%
33
0.0%
0
1.9%
1
2.7%
2
1.6%
1
0.0%
0
1.8%
1
8.2%
5
5.2%
3
0.0%
0
6.2%
4
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.4%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
1.7%
1
1.7%
1
1.6%
1
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
1.6%
1
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
¶
**
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone
At least ACSSuT† 
At least ACT/S‡
At least AT/S§
At least ANT/S¶
At least ACSSuTAuCx**
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
Year
Total Isolates
Resistance Pattern
No resistance detected 
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4. Escherichia coli O157 
 
Table 47.  Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to 
antimicrobial agents, 2013 (N=177) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.6 0.6 [0.0 - 3.1] 5.6 79.1 11.3 2.8 0.6 0.6
Kanamycin 0.0 0.0 [0.0 - 2.1] 100.0
Streptomycin N/A 6.8 [3.5 - 11.5] 93.2 1.1 5.6
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.6 1.1 [0.1 - 4.0] 2.3 5.1 85.9 5.1 0.6 0.6 0.6
Cephems Ceftiofur 0.0 0.6 [0.0 - 3.1] 1.1 7.9 80.2 9.6 0.6 0.6
Ceftriaxone 0.0 0.6 [0.0 - 3.1] 99.4 0.6
Macrolide Azithromycin N/A 0.0 [0.0 - 2.1] 5.1 62.7 30.5 0.6 1.1
Penicillins Ampicillin 0.0 4.5 [2.0 - 8.7] 4.5 63.8 26.6 0.6 1.1 3.4
Quinolones Ciprofloxacin 0.0 0.6 [0.0 - 3.1] 94.9 1.7 2.3 0.6 0.6
Nalidixic acid N/A 2.8 [0.9 - 6.5] 1.7 80.2 14.1 0.6 0.6 2.8
Cephems Cefoxitin 2.3 1.1 [0.1 - 4.0] 0.6 6.2 68.9 20.9 2.3 1.1
Folate pathway inhibitors Sulf isoxazole N/A 5.6 [2.7 - 10.1] 80.2 9.6 3.4 1.1 5.6
Trimethoprim-sulfamethoxazole N/A 1.7 [0.3 - 4.9] 94.4 2.3 1.7 1.7
Phenicols Chloramphenicol 0.6 2.8 [0.9 - 6.5] 1.1 14.1 81.4 0.6 2.8
Tetracyclines Tetracycline 1.7 8.5 [4.8 - 13.6] 89.8 1.7 1.1 7.3
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if  no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates w ith MIC (µg/mL)**
 
 
Figure 15.  Antimicrobial resistance pattern for Escherichia coli O157, 2013 
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Table 48.  Percentage and number of Escherichia coli O157 isolates resistant to antimicrobial agents, 
2004–2013
2004
169
2005
194
2006
233
2007
189
2008
161
2009
187
2010
170
2011
162
2012
166
2013
177
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Amikacin
(MIC ≥ 64)
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Gentamicin
(MIC ≥ 16)
0.6%
1
0.5%
1
0.0%
0
0.0%
0
1.2%
2
0.5%
1
0.6%
1
0.6%
1
0.6%
1
0.6%
1
Kanamycin
(MIC ≥ 64)
0.0%
0
0.5%
1
0.4%
1
0.0%
0
0.0%
0
0.5%
1
1.2%
2
1.9%
3
0.0%
0
0.0%
0
Streptomycin
(MIC ≥ 64)
1.8%
3
2.1%
4
2.6%
6
2.1%
4
1.9%
3
4.8%
9
2.4%
4
4.3%
7
2.4%
4
6.8%
12
β-lactam/β-lactamase inhibitor 
combinations
Amoxicillin-clavulanic acid
(MIC ≥ 32/16)
0.0%
0
0.0%
0
1.3%
3
0.0%
0
0.6%
1
0.5%
1
0.0%
0
0.0%
0
0.6%
1
1.1%
2
Ceftiofur
(MIC ≥ 8)
0.0%
0
0.0%
0
1.3%
3
0.0%
0
0.6%
1
0.0%
0
0.0%
0
0.0%
0
0.6%
1
0.6%
1
Ceftriaxone
(MIC ≥ 4)
0.0%
0
0.0%
0
1.3%
3
0.0%
0
0.6%
1
0.0%
0
0.0%
0
0.0%
0
0.6%
1
0.6%
1
Macrolides Azithromycin
(MIC ≥ 32)
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
0.0%
0
0.6%
1
0.0%
0
Penicillins Ampicillin
(MIC ≥ 32)
1.2%
2
4.1%
8
2.6%
6
2.1%
4
3.7%
6
4.3%
8
1.8%
3
3.7%
6
1.8%
3
4.5%
8
Ciprofloxacin
(MIC ≥ 4)
0.0%
0
0.0%
0
0.4%
1
0.5%
1
0.0%
0
0.5%
1
0.0%
0
0.6%
1
0.0%
0
0.6%
1
Nalidixic Acid
(MIC ≥ 32)
1.8%
3
1.5%
3
2.1%
5
2.1%
4
1.2%
2
2.1%
4
1.2%
2
1.2%
2
2.4%
4
2.8%
5
Cephems Cefoxitin
(MIC ≥ 32)
0.6%
1
0.0%
0
1.3%
3
0.0%
0
1.2%
2
0.5%
1
0.0%
0
0.0%
0
0.6%
1
1.1%
2
Sulfisoxazole
(MIC ≥ 512)
1.8%
3
6.7%
13
3.0%
7
2.6%
5
3.1%
5
6.4%
12
4.7%
8
4.9%
8
3.6%
6
5.6%
10
Trimethoprim-sulfamethoxazole
(MIC ≥ 4/76)
0.0%
0
0.5%
1
0.4%
1
1.1%
2
1.2%
2
4.3%
8
1.2%
2
2.5%
4
1.2%
2
1.7%
3
Phenicols Chloramphenicol
(MIC ≥ 32)
0.6%
1
1.0%
2
1.3%
3
0.5%
1
0.6%
1
1.1%
2
0.6%
1
1.2%
2
1.8%
3
2.8%
5
Tetracyclines Tetracycline
(MIC ≥ 16)
1.8%
3
8.8%
17
4.7%
11
4.2%
8
1.9%
3
7.5%
14
4.7%
8
4.9%
8
5.4%
9
8.5%
15
*
†
II
Folate pathway inhibitors
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Aminoglycosides
Cephems
Quinolones
 
 
 
Table 49.  Resistance patterns of Escherichia coli O157 isolates, 2004–2013 
2004
169
2005
194
2006
233
2007
189
2008
161
2009
187
2010
170
2011
162
2012
166
2013
177
94.7%
160
87.6%
170
91.8%
214
92.6%
175
91.9%
148
89.8%
168
93.5%
159
92.6%
150
92.2%
153
84.7%
150
5.3%
9
12.4%
24
8.2%
19
7.4%
14
8.1%
13
10.2%
19
6.5%
11
7.4%
12
7.8%
13
15.3%
27
2.4%
4
6.7%
13
4.7%
11
2.6%
5
3.1%
5
7.5%
14
4.7%
8
4.9%
8
4.2%
7
7.9%
14
1.2%
2
5.2%
10
3.4%
8
2.1%
4
2.5%
4
5.9%
11
4.1%
7
4.3%
7
3.0%
5
6.2%
11
0.6%
1
1.0%
2
2.1%
5
1.1%
2
1.2%
2
4.3%
8
1.8%
3
2.5%
4
1.8%
3
2.3%
4
0.0%
0
0.0%
0
0.9%
2
0.5%
1
0.0%
0
0.5%
1
0.0%
0
0.6%
1
1.2%
2
1.1%
2
0.0%
0
0.0%
0
0.9%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.6%
1
1.2%
2
1.1%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.6%
1
0.0%
0
0.0%
0
1.2%
2
0.6%
1
1.1%
2
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.4%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
*
†
‡
§
At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
Year
Total Isolates
Resistance Pattern
No resistance detected 
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least ACSSuT† 
At least ACT/S‡
At least ACSSuTAuCx§
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5. Campylobacter 
  
Table 50.  Frequency of Campylobacter species, 2013 
n (%)
Campylobacter jejuni 1182 (86.2)
Campylobacter coli 142 (10.3)
Other 48 (3.5)
Total 1372 (100)
Species 2013
 
 
 
Table 51.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to 
antimicrobial agents, 2013 (N=1182)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin N/A 1.6 [1.0 - 2.5] 0.1 45.8 51.9 0.6 0.1 0.1 1.4
Ketolide Telithromycin N/A 2.0 [1.3 - 3.0] 3.6 22.4 41.7 27.8 2.4 0.3 1.8
Macrolides Azithromycin N/A 2.2 [1.4 - 3.2] 12.5 45.4 34.3 5.6 0.1 2.1
Erythromycin N/A 2.2 [1.4 - 3.2] 0.4 21.2 42.6 29.9 3.4 0.3 0.2 0.1 1.9
Quinolones Ciprofloxacin N/A 22.3 [19.9 - 24.7] 0.3 19.7 47.0 9.5 1.2 0.1 0.1 8.5 8.1 3.0 1.8 0.6
Nalidixic acid N/A 22.2 [19.8 - 24.6] 63.1 13.9 0.8 0.3 21.9
Lincosamides Clindamycin N/A 3.2 [2.3 - 4.4] 0.1 5.7 54.0 29.9 7.2 1.0 0.3 0.1 0.9 0.5 0.4
Phenicols Florfenicol N/A 1.2 [0.6 - 2.0] 1.4 76.1 19.5 1.9 1.0 0.2
Tetracyclines Tetracycline N/A 49.1 [46.2 - 52.0] 1.4 23.9 20.1 4.1 1.4 0.7 0.1 0.3 0.7 5.3 42.0
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. ECOFFs w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
Figure 16.  Antimicrobial resistance pattern for Campylobacter jejuni, 2013 
 
 
  
 
Gentamicin 
Telithromycin 
Azithromycin 
Erythromycin 
Ciprofloxacin 
Nalidixic acid 
Clindamycin 
Florfenicol 
Tetracycline 
Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
 65 
Table 52.  Percentage and number of Campylobacter jejuni isolates resistant to antimicrobial agents, 
2004–2013
2004
320
2005
788
2006
709
2007
992
2008
1033
2009
1350
2010
1159
2011
1275
2012
1191
2013
1182
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin
(MIC ≥ 4)
2.2%
7
0.1%
1
0.0%
0
0.8%
8
1.1%
11
0.6%
8
0.6%
7
1.0%
13
1.0%
12
1.6%
19
Ketolides Telithromycin
(MIC ≥ 8)
Not
Tested
0.8%
6
1.0%
7
1.3%
13
2.2%
23
1.9%
25
2.4%
28
2.6%
33
1.4%
17
2.0%
24
Azithromycin
(MIC ≥ 0.5)
9.4%
30
2.7%
21
1.3%
9
1.8%
18
2.6%
27
1.9%
26
2.7%
31
4.9%
63
1.8%
21
2.2%
26
Erythromycin
(MIC ≥ 8)
0.9%
3
1.5%
12
0.8%
6
1.6%
16
2.2%
23
1.5%
20
1.2%
14
1.8%
23
1.5%
18
2.2%
26
Ciprofloxacin
(MIC ≥ 1)
18.1%
58
21.6%
170
19.6%
139
26.0%
258
22.6%
233
23.1%
312
22.0%
255
24.1%
307
25.3%
301
22.3%
263
Nalidixic Acid
(MIC ≥ 32)
19.1%
61
22.5%
177
19.5%
138
26.5%
263
22.8%
236
23.1%
312
22.1%
256
24.1%
307
25.5%
304
22.2%
262
Lincosamides Clindamycin
(MIC ≥ 1)
5.6%
18
3.2%
25
2.4%
17
3.5%
35
3.8%
39
2.9%
39
14.1%
163
21.5%
274
10.8%
129
3.2%
38
Chloramphenicol
(MIC ≥ 32)
1.6%
5
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Florfenicol
(MIC ≥ 8)
Not
Tested
0.4%
3
0.0%
0
0.0%
0
0.6%
6
0.6%
8
1.5%
17
2.1%
27
1.4%
17
1.2%
14
Tetracyclines Tetracycline
(MIC ≥ 2)
47.5%
152
43.7%
344
48.7%
345
45.7%
453
45.3%
468
44.1%
595
44.2%
512
48.3%
616
47.8%
569
49.1%
580
*
†
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Phenicols
Year
Total Isolates
Rank*
I
Macrolides
Quinolones
 
 
 
 
Table 53.  Resistance patterns of Campylobacter jejuni isolates, 2004–2013 
2004
320
2005
788
2006
709
2007
992
2008
1033
2009
1350
2010
1159
2011
1275
2012
1191
2013
1182
41.9%
134
46.3%
365
42.5%
301
44.3%
439
45.2%
467
45.9%
620
39.5%
458
33.0%
421
38.6%
460
44.6%
527
58.1%
186
53.7%
423
57.5%
408
55.7%
553
54.8%
566
54.1%
730
60.5%
701
67.0%
854
61.4%
731
55.4%
655
19.7%
63
16.2%
128
13.1%
93
18.9%
187
15.8%
163
15.1%
204
19.0%
220
23.5%
300
20.0%
238
17.3%
204
5.3%
17
2.4%
19
1.3%
9
2.0%
20
3.5%
36
2.7%
37
4.2%
49
7.5%
96
4.8%
57
3.1%
37
1.9%
6
1.0%
8
0.7%
5
1.3%
13
1.9%
20
1.6%
21
1.9%
22
3.6%
46
1.8%
21
2.2%
26
0.3%
1
0.0%
0
0.3%
2
1.1%
11
1.5%
16
1.0%
13
1.0%
12
1.9%
24
0.9%
11
1.8%
21
2.2%
7
1.4%
11
0.7%
5
1.4%
14
1.5%
15
1.2%
16
1.3%
15
3.0%
38
1.3%
16
1.9%
22
*
At least quinolone and macrolide resistant
CLSI: Clinical and Laboratory Standards Institute
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
Year
Total Isolates
Resistance ≥ 1 CLSI* class
Resistance ≥ 2 CLSI* classes
Resistance Pattern
No resistance detected 
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Table 54.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to 
antimicrobial agents, 2013 (N=142)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin N/A 2.1 [0.4 - 6.0] 14.8 72.5 10.6 2.1
Ketolide Telithromycin N/A 21.8 [15.3 - 29.5] 0.7 10.6 19.7 5.6 25.4 16.2 7.7 14.1
Macrolides Azithromycin N/A 16.9 [11.1 - 24.1] 0.7 12.0 38.7 29.6 2.1 16.9
Erythromycin N/A 17.6 [11.7 - 24.9] 5.6 21.1 24.6 16.9 13.4 0.7 0.7 0.7 16.2
Quinolones Ciprofloxacin N/A 34.5 [26.7 - 42.9] 4.2 26.1 28.2 7.0 0.7 7.0 13.4 10.6 2.1 0.7
Nalidixic acid N/A 35.2 [27.4 - 43.7] 19.0 38.7 7.0 0.7 3.5 31.0
Lincosamides Clindamycin N/A 21.1 [14.7 - 28.8] 4.9 30.3 28.2 15.5 3.5 1.4 4.9 9.2 2.1
Phenicols Florfenicol N/A 0.7 [0.0 - 3.9] 1.4 35.9 49.3 12.7 0.7
Tetracyclines Tetracycline N/A 51.4 [42.9 - 59.9] 4.2 21.8 16.9 5.6 0.7 50.7
*
†
‡
§
¶
**
I
II
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. ECOFFs w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 
 
 
Figure 17.  Antimicrobial resistance pattern for Campylobacter coli, 2013 
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Table 55.  Percentage and number of Campylobacter coli isolates resistant to antimicrobial agents, 2004–
2013
2004
26
2005
99
2006
97
2007
105
2008
115
2009
142
2010
115
2011
148
2012
134
2013
142
CLSI† Antimicrobial
Class
Antibiotic
(Resistance breakpoint)
Aminoglycosides Gentamicin
(MIC ≥ 4)
3.8%
1
3.0%
3
1.0%
1
0.0%
0
1.7%
2
3.5%
5
12.2%
14
12.2%
18
6.0%
8
2.1%
3
Ketolides Telithromycin
(MIC ≥ 8)
Not
Tested
8.1%
8
9.3%
9
9.5%
10
10.4%
12
7.0%
10
13.9%
16
10.8%
16
11.2%
15
21.8%
31
Azithromycin
(MIC ≥ 1)
3.8%
1
4.0%
4
9.3%
9
5.7%
6
10.4%
12
3.5%
5
7.0%
8
5.4%
8
9.0%
12
16.9%
24
Erythromycin
(MIC ≥ 16)
3.8%
1
4.0%
4
8.2%
8
5.7%
6
10.4%
12
3.5%
5
5.2%
6
2.7%
4
9.0%
12
17.6%
25
Ciprofloxacin
(MIC ≥ 1)
30.8%
8
25.3%
25
21.6%
21
28.6%
30
29.6%
34
23.9%
34
30.4%
35
36.5%
54
33.6%
45
34.5%
49
Nalidixic Acid
(MIC ≥ 32)
34.6%
9
27.3%
27
23.7%
23
30.5%
32
29.6%
34
24.6%
35
30.4%
35
35.8%
53
33.6%
45
35.2%
50
Lincosamides Clindamycin
(MIC ≥ 2)
11.5%
3
8.1%
8
14.4%
14
9.5%
10
14.8%
17
7.7%
11
17.4%
20
16.9%
25
16.4%
22
21.1%
30
Chloramphenicol
(MIC ≥ 32)
0.0%
0
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Not
Tested
Florfenicol
(MIC ≥ 8)
Not
Tested
1.0%
1
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.0%
0
0.7%
1
1.5%
2
0.7%
1
Tetracyclines Tetracycline
(MIC ≥ 4)
38.5%
10
31.3%
31
39.2%
38
42.9%
45
39.1%
45
45.1%
64
50.4%
58
50.7%
75
45.5%
61
51.4%
73
*
†
II
Phenicols
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Year
Total Isolates
Rank*
I
Macrolides
Quinolones
 
 
 
 
Table 56.  Resistance patterns of Campylobacter coli isolates, 2004–2013 
2004
26
2005
99
2006
97
2007
105
2008
115
2009
142
2010
115
2011
148
2012
134
2013
142
34.6%
9
49.5%
49
43.3%
42
38.1%
40
43.5%
50
43.7%
62
33.9%
39
31.1%
46
42.5%
57
31.7%
45
65.4%
17
50.5%
50
56.7%
55
61.9%
65
56.5%
65
56.3%
80
66.1%
76
68.9%
102
57.5%
77
68.3%
97
26.9%
7
19.2%
19
20.6%
20
21.0%
22
28.7%
33
21.1%
30
38.3%
44
43.2%
64
32.8%
44
35.9%
51
0.0%
0
7.1%
7
10.3%
10
8.6%
9
8.7%
10
7.0%
10
13.9%
16
14.9%
22
12.7%
17
21.1%
30
0.0%
0
4.0%
4
6.2%
6
5.7%
6
7.0%
8
4.2%
6
7.0%
8
4.7%
7
9.0%
12
14.1%
20
0.0%
0
2.0%
2
2.1%
2
1.0%
1
3.5%
4
2.8%
4
3.5%
4
1.4%
2
6.0%
8
8.5%
12
0.0%
0
2.0%
2
4.1%
4
1.9%
2
4.3%
5
2.8%
4
3.5%
4
3.4%
5
8.2%
11
9.2%
13
*
Resistance ≥ 2 CLSI* classes
Resistance ≥ 3 CLSI* classes
Resistance ≥ 4 CLSI classes
Resistance ≥ 5 CLSI* classes
At least quinolone and macrolide resistant
CLSI: Clinical and Laboratory Standards Institute
Resistance ≥ 1 CLSI* class
Year
Total Isolates
Resistance Pattern
No resistance detected 
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6. Vibrio species other than V. cholerae 
 
Table 57.  Frequency* of Vibrio species other than V. cholerae, 2009–2013 
n (%) n (%) n (%) n (%) n (%)
Vibrio parahaemolyticus 149 (53.0) 179 (54.4) 201 (50.5) 370 (61.4) 317 (52.2)
Vibrio alginolyticus 46 (16.4) 49 (14.9) 103 (25.9) 117 (19.4) 122 (20.1)
Vibrio vulnificus 50 (17.8) 61 (18.5) 63 (15.8) 65 (10.8) 87 (14.3)
Vibrio fluvialis 21 (7.5) 24 (7.3) 18 (4.5) 28 (4.6) 40 (6.6)
Vibrio mimicus 11 (3.9) 9 (2.7) 9 (2.3) 11 (1.8) 27 (4.4)
Vibrio harveyi 0 (0) 2 (0.6) 4 (1.0) 3 (0.5) 5 (0.8)
Other 4 (1.4) 5 (1.5) 0 (0) 9 (1.5) 9 (1.5)
2013*Species* 2009 2010 2011 2012
 
* Frequencies reflect the number of isolates tested, not number of culture-confirmed cases. See Methods for varying sampling method by species. 
 
Table 58.  Minimum inhibitory concentrations (MICs) and resistance of isolates of Vibrio species other 
than V. cholerae to antimicrobial agents, 2013 (N=607) 
CLSI† Antimicrobial Class
   Antimicrobial Agent Species  (# of isolates) %I‡ %R§ [95% CI]¶ 0.002 0.004 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Aminoglycosides
   Gentamicin All (607) 0.2 0.0 [0.0 - 0.6] 0.5 2.1 27.2 67.2 2.8 0.2
parahaemolyticus  (317) 0.0 0.0 [0.0 - 1.2] 0.9 18.0 80.1 0.9
alginolyticus  (122) 0.0 0.0 [0.0 - 3.0] 1.6 0.8 42.6 54.1 0.8
vulnificus  (87) 1.1 0.0 [0.0 - 4.2] 1.1 2.3 81.6 13.8 1.1
Cephems
   Cefotaxime All (607) 0.7 0.3 [0.0 - 1.2] 5.4 8.4 43.7 36.7 2.8 2.0 0.7 0.2 0.2
parahaemolyticus  (317) 0.0 0.0 [0.0 - 1.2] 0.6 6.0 38.8 52.7 0.9 0.9
alginolyticus  (122) 0.0 0.0 [0.0 - 3.0] 0.8 0.8 63.1 33.6 1.6
vulnificus  (87) 0.0 0.0 [0.0 - 4.2] 2.3 24.1 67.8 4.6 1.1
   Ceftazidime All (607) 0.2 0.0 [0.0 - 0.6] 0.7 12.9 37.9 46.1 2.0 0.3 0.2
parahaemolyticus  (317) 0.0 0.0 [0.0 - 1.2] 0.6 10.4 22.7 63.1 2.5 0.6
alginolyticus  (122) 0.0 0.0 [0.0 - 3.0] 0.8 34.4 48.4 16.4
vulnificus  (87) 0.0 0.0 [0.0 - 4.2] 62.1 35.6 2.3
Penems
   Imipenem All (607) 0.0 0.0 [0.0 - 0.6] 43.3 43.0 1.8 0.7 8.7 2.5
parahaemolyticus  (317) 0.0 0.0 [0.0 - 1.2] 60.6 38.8 0.6
alginolyticus  (122) 0.0 0.0 [0.0 - 3.0] 49.2 49.2 1.6
vulnificus  (87) 0.0 0.0 [0.0 - 4.2] 4.6 79.3 12.6 3.4
Penicillins
   Ampicillin All (607) 12.0 46.0 [41.9 - 50.0] 0.2 0.2 5.3 8.9 10.0 17.5 12.0 16.5 5.4 2.3 0.8 20.9
parahaemolyticus  (317) 19.9 40.7 [35.2 - 46.3] 0.3 0.3 0.9 11.4 26.5 19.9 27.1 6.9 2.2 0.6 3.8
alginolyticus  (122) 1.6 95.9 [90.7 - 98.7] 0.8 1.6 1.6 4.1 4.9 3.3 0.8 82.8
vulnificus  (87) 0.0 2.3 [0.3 - 8.1] 35.6 57.5 3.4 1.1 1.1 1.1
Quinolones
   Ciprofloxacin All (607) 0.7 0.0 [0.0 - 0.6] 0.7 2.8 4.8 2.8 13.5 43.2 30.0 1.6 0.7
parahaemolyticus  (317) 0.9 0.0 [0.0 - 1.2] 0.6 0.3 0.9 62.5 34.4 0.3 0.9
alginolyticus  (122) 0.0 0.0 [0.0 - 3.0] 4.1 6.6 36.1 51.6 1.6
vulnificus  (87) 1.1 0.0 [0.0 - 4.2] 1.1 1.1 8.0 79.3 5.7 1.1 2.3 1.1
   Nalidixic acid†† All (607) N/A N/A N/A 0.2 0.5 3.8 23.1 60.0 11.7 0.7 0.2
parahaemolyticus  (317) N/A N/A N/A 0.3 0.9 15.8 70.3 12.6
alginolyticus  (122) N/A N/A N/A 3.3 23.8 54.9 15.6 2.5
vulnificus  (87) N/A N/A N/A 4.6 33.3 55.2 6.9
Folate pathway inhibitors
   Trimethoprim-sulfamethoxazole All (607) N/A 0.0 [0.0 - 0.6] 0.2 0.3 5.1 54.0 39.4 0.8 0.2
parahaemolyticus  (317) N/A 0.0 [0.0 - 1.2] 0.3 29.7 69.4 0.6
alginolyticus  (122) N/A 0.0 [0.0 - 3.0] 0.8 1.6 8.2 79.5 9.0 0.8
vulnificus  (87) N/A 0.0 [0.0 - 4.2] 17.2 80.5 1.1 1.1
Phenicols
   Chloramphenicol†† All (607) N/A N/A N/A 0.3 5.6 82.4 11.4 0.2 0.2
parahaemolyticus  (317) N/A N/A N/A 0.6 83.3 16.1
alginolyticus  (122) N/A N/A N/A 1.6 6.6 86.1 4.9 0.8
vulnificus  (87) N/A N/A N/A 20.7 78.2 1.1
Tetracyclines
   Tetracycline All (607) 0.0 0.0 [0.0 - 0.6] 0.5 6.6 68.0 23.7 1.2
parahaemolyticus  (317) 0.0 0.0 [0.0 - 1.2] 0.3 0.9 71.9 26.8
alginolyticus  (122) 0.0 0.0 [0.0 - 3.0] 5.7 77.0 17.2
vulnificus  (87) 0.0 0.0 [0.0 - 4.2] 1.1 26.4 70.1 2.3
*
†
‡
§
¶
**
††
Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix A, Table A1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists or no CLSI breakpoints have been established
Percentage of isolates that w ere resistant; N/A indicates that no CLSI breakpoints have been established
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method; N/A indicates that no CLSI breakpoints have been established
The unshaded areas indicate the dilution range of the Etest® strips used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the 
percentages of isolates w ith MICs greater than the highest concentrations on the Etest® strip. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to or less than the low est tested concentration. CLSI 
breakpoints w ere used w hen available.
CLSI MIC interpretive criteria have not been established
Rank*
Percentage of isolates Percentage of all isolates w ith MIC (µg/mL)**
I
II
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Table 59.  Percentage and number of isolates of Vibrio species other than V. cholerae resistant to 
ampicillin, 2009–2013 
2009 2010 2011 2012 2013
9.4% 8.4% 40.3% 14.1% 40.7%
14 15 81 52 129
82.6% 89.8% 95.1% 98.3% 95.9%
38 44 98 115 117
2.0% 0% 4.8% 1.5% 2.3%
1 0 3 1 2
33.3% 12.5% 44.4% 21.4% 50.0%
7 3 8 6 20
9.1% 0% 0% 9.1% 7.4%
1 0 0 1 2
N/A* 50.0% 100% 100% 80.0%
0 1 4 3 4
25.0% 0% N/A* 22.2% 55.6%
1 0 0 2 5
22.1% 19.1% 48.7% 29.9% 46.0%
62 63 194 180 279
*
Vibrio harveyi
Other
Total
N/A indicates that no isolates were received and tested
Species
Vibrio parahaemolyticus
Vibrio alginolyticus
Vibrio vulnificus
Vibrio fluvialis
Vibrio mimicus
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The following figures display resistance to selected agents and combinations of agents from 1996–2013 for 
nontyphoidal Salmonella, 1999–2013 for Salmonella ser. Typhi, 1997–2013 for Campylobacter, and 1999–2013 
for Shigella. 
 
 
Figure 18.  Percentage of nontyphoidal Salmonella isolates resistant to nalidixic acid, by year, 1996–2013
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Figure 19.  Percentage of nontyphoidal Salmonella isolates resistant to ceftriaxone, by year, 1996–2013
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Figure 20.  Percentage of Salmonella ser. Enteritidis isolates resistant to nalidixic acid, by year, 1996–
2013
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Figure 21.  Percentage of Salmonella ser. Heidelberg isolates resistant to ceftriaxone, by year, 1996–2013
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Figure 22.  Percentage of Salmonella ser. Typhimurium isolates resistant to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide, and tetracycline (ACSSuT), by year, 1996–2013
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Figure 23.  Percentage of Salmonella ser. Newport isolates resistant to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone 
(ACSSuTAuCx), by year, 1996–2013
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Figure 24.  Percentage of nontyphoidal Salmonella isolates resistant to 1 or more antimicrobial classes, 
by year, 1996–2013
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Figure 25.  Percentage of nontyphoidal Salmonella isolates resistant to 3 or more antimicrobial classes, 
by year, 1996–2013
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Figure 26.  Percentage of Salmonella ser. Typhi isolates resistant to nalidixic acid, by year, 1999–2013
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Figure 27.  Percentage of Campylobacter jejuni isolates resistant to ciprofloxacin, by year, 1997–2013
 
 
 
 
Figure 28.  Percentage of Campylobacter coli isolates resistant to ciprofloxacin, by year, 1997–2013
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 Figure 29.  Percentage of Shigella isolates resistant to nalidixic acid, by year, 1999–2013
76 
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In 2011 the World Health Organization (WHO) convened a panel of experts to update a list of antimicrobial agents 
ranked according to their relative importance to human medicine (WHO, 2011).  The participants categorized 
antimicrobial agents as either Critically Important, Highly Important, or Important based upon two criteria: (1) used 
as sole therapy or one of the few alternatives to treat serious human disease and (2) used to treat disease caused 
by either organisms that may be transmitted via non–human sources or diseases caused by organisms that may 
acquire resistance genes from non–human sources  Antimicrobial agents tested in NARMS have been included in 
the WHO categorization table. 
 
 Antimicrobial agents are critically important if both criteria (1) and (2) are true. 
 Antimicrobial agents are highly important if either criterion (1) or (2) is true. 
 Antimicrobial agents are important if neither criterion is true. 
 
Table A1.  WHO categorization of antimicrobials of critical importance to human medicine 
WHO 
Category 
Level 
Importance CLSI* Class 
Antimicrobial Agent tested in 
NARMS 
I Critically important 
Aminoglycosides 
Amikacin 
Gentamicin 
Kanamycin 
Streptomycin 
β-lactam / β-lactamase inhibitor 
combinations 
Amoxicillin-clavulanic acid 
Piperacillin-tazobactam 
Cephems  
Cefepime 
Cefotaxime 
Ceftazidime 
Ceftriaxone 
Ketolides Telithromycin 
Macrolides 
Azithromycin 
Erythromycin 
Monobactams Aztreonam 
Penems Imipenem 
Penicillins Ampicillin 
Quinolones 
Ciprofloxacin 
Nalidixic acid 
    
II Highly important 
Cephems 
Cefoxitin 
Cephalothin 
Folate pathway inhibitors 
Sulfamethoxazole / Sulfisoxazole 
Trimethoprim-sulfamethoxazole 
Lincosamides Clindamycin 
Phenicols Chloramphenicol 
Tetracyclines Tetracycline 
 
* CLSI: Clinical and Laboratory Standards Institute 
Appendix A.  WHO Categorization of Antimicrobial Agents 
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Repeat testing of an isolate must be done when one or more of the following conditions occur: 
 No growth on panel 
 Growth in all wells  
 Multiple skip patterns  
 Apparent contamination in wells or isolate preparation 
 Unlikely or discordant susceptibility results (Table B1) 
If an isolate is retested, data for all antimicrobial agents should be replaced with the new test results. Categorical 
changes may require a third test (and may indicate a mixed culture).  
 
Uncommon but possible test results (Table B2) may represent emerging resistance phenotypes. Retesting is 
encouraged.   
 
Table B1.  Retest criteria for unlikely or discordant resistance phenotypes 
Organism(s) Resistance phenotype (MIC values in µg/mL) Comments 
Salmonella /    
E. coli O157 / 
Shigella 
ceftiofurR (≥8) OR ceftriaxoneR (≥4) AND 
ampicillinS (≤8) 
The presence of an ESBL* or AmpC beta-
lactamase should confer resistance to ampicillin 
ceftiofurR (≥8) AND ceftriaxoneS (≤1) OR 
ceftiofurS (≤2) AND ceftriaxoneR (≥4)  
Both antimicrobial agents are 3rd generation β-
lactams and should have equal susceptibility 
interpretations 
ampicillinS (≤8) AND  
amoxicillin-clavulanic acidR (≥32/16) 
 
Salmonella and  
E. coli O157 
sulfisoxazoleS (≤256) AND  
trimethoprim-sulfamethoxazoleR (≥4/76) 
 
Salmonella  nalidixic acidS (≤16) AND 
ciprofloxacinR (≥1) 
The stepwise selection of mutations in the QRDR†  
does not support this phenotype, although it may 
occur with plasmid-mediated mechanisms 
E. coli O157 and 
Shigella 
nalidixic acidS (≤16) AND  
ciprofloxacinR (≥4) 
The stepwise selection of mutations in the QRDR† 
does not support this phenotype 
Campylobacter 
jejuni and coli 
nalidixic acidS (≤16) AND  
ciprofloxacinR (≥1) In Campylobacter, one mutation is sufficient to 
confer resistance to both nalidixic acid and 
ciprofloxacin nalidixic acid
R (≥32) AND 
ciprofloxacinS (≤0.5) 
Campylobacter 
jejuni 
erythromycinS (≤4) AND  
azithromycinR (≥0.5)  
Erythromycin is class representative for 14- and 
15-membered macrolides (azithromycin, 
clarithromycin, roxithromycin, and dirithromycin) 
erythromycinR  (≥8) AND  
azithromycinS (≤0.25) 
Campylobacter 
coli 
erythromycinS (≤8) AND  
azithromycinR (≥1) 
erythromycinR  (≥16) AND  
azithromycinS (≤0.5) 
 
* Extended-spectrum beta-lactamase 
† Quinolone resistance-determining regions 
 
Table B2.  Uncommon resistance phenotypes for which retesting is encouraged 
Organism(s) Resistance phenotype (MIC values in µg/mL) 
Salmonella /    
E. coli O157 / 
Shigella 
Pan-resistance  
Resistance to azithromycin (>16) 
ceftriaxone and/or ceftiofur MIC ≥2 AND  
ciprofloxacin MIC ≥0.125 and/or nalidixic acid MIC ≥32 
Campylobacter 
jejuni and coli 
Pan-resistance  
Resistance to gentamicin (≥4)  
Resistance to florfenicol (≥8) 
Vibrio Resistance to ciprofloxacin (>2) 
Resistance to tetracycline (>8) 
Resistance to trimethoprim-sulfamethoxazole (>2) 
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